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1. Introduction: 
Gynecologic cancers are leading causes of death in women worldwide. 
Collectively labeled as gynecologic cancer, ovarian, uterine cervix, uterine corpus, 
vaginal, and vulvar cancers are leading causes of cancer death in women around 
the world.
(1)
 
 
2. Incidence and Epidemiology: 
Cervical cancer remains the 4
th
 most often diagnosed cancer and therefore 
the 4
th
 leading cause of death due to cancer in women worldwide.
(2)
 
Worldwide, 1.1 million women were diagnosed with a gynecologic cancer 
and an estimated 513,000 (47%) died of their disease.
(3)
 
Cervical cancer remains the most common cancer in women in Eastern and 
Middle Africa.
(3)
 
 
3. Risk Factors: 
Human papillomavirus (HPV) infection is the most significant risk factor for 
cervical cancer, as there's a really strong link between HPV infection and cervical 
cancer.
(4)
 
Other risk elements for cervical cancer encompass the subsequent: cigarette 
smoking, high parity, long-term use of oral contraceptives, Immunosuppression, 
multiple sexual partners, but smoking appeared to be the most significant 
environmental risk factor.
(5)
 
Cancer Cervix risk is six times higher in females with HIV versus females in 
the general population.
(6)
 
Females whose food do not contain enough fruits and vegetables could be at 
greater hazard for cancer cervix.
(7)
 
In 2020, an estimated about 13,800 cases of cervical cancer are getting to be 
diagnosed and about 4,290 deaths will occur in the US. The incidence rate has 
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dropped by more than half since the mid-1970s, largely due to the widespread of 
screening with the Pap test. Studies suggest that may be due to HPV vaccine 
uptake. Moreover, death rate has also dropped by more than half since the mid-
1970s due to declines in incidence and the early detection of cancer through 
screening.
(8)
 
Risk of cancer cervix may be decreased by regular cervical cancer screening 
tests. A pap test is used to screen for cervical cancer. After certain positive pap test 
results, HPV test may be done.
(9)
 
 
4. Diagnosis:  
 Symptoms: Early stages are asymptomatic (underscoring the importance of 
screening)….  
1. Bleeding (most common presentation) 
- Contact bleeding (always suspect cancer cervix). 
- Postmenopausal bleeding (always suspect endometrial cancer)  
2. Discharge: serosanginous or offensive (infected)  
3. Pain (late): low back pain radiating to back of lower extremities  
4. Bowel or urinary symptoms, such as pressure-related complaints, 
hematuria, bleeding per rectum, or vaginal passage of urine or stool. 
 Signs: 
1. General: Cachexia - Anemia - Uremia in advanced cases  
2. Abdominal: No pelviabdominal mass (except if pyometra or metastasis)  
3. Local:  
- Per Vaginal examination (P/V): any of the pathologic forms of 
ectocervix or endocervix is seen  
- Per Rectal examination (P/R): is the only way to assess cervical size and 
the best way to assess the degree parametrial infiltration.
(10-11)
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5. Clinical staging & Investigations:  
a) Physical examination: (by an experienced examiner under anesthesia)  
- Speculum, bimanual, and rectovaginal.  
- Palpation of groin and supraclavicular LNs  
b) Cervical biopsy:  
- Direct or colposcopic.  
- Endocervical curettage if no lesion is colposcopically detected  
- Conization: in highly suspicious cases with negative gross and colposcopic 
findings, as well as, when microinvasion is suspected.  
c) Endoscopy  
- Hysteroscopy: for uterine spread.  
- Cystoscopy: for bladder spread (finger like projections and not bullous 
edema)  
- Proctoscopy: for rectal spread.  
d) Imaging studies: 
- CT or MRI for accurate assessment of tumor spread. 
- Intravenous pyelogram (IVP) for ureteric extension.  
- Chest and Abdomen radiograph for evaluation for distant metastases.(11) 
 
6. Staging: 
(FIGO) “the International Federation of Gynecology & obstetrics” decided 
those analysis procedures for staging can be confined to colposcopy, biopsy, 
conization of cervix, cystoscopy, & procto-sigmiodoscopy. More complicated 
radiological & surgical techniques aren't presented in the FIGO classification. 
However in the United States of America computed tomography (CT), magnetic 
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resonance imaging (MRI), Combined Positron emission tomography/computed 
tomography (PET/CT), and surgical staging are used to guide treatment options.
(12)
 
Once cancer cervix is diagnosed, radiological imaging is indicated to know 
how far the cancer has spread. Recommended radiological imaging are chest x-ray, 
CT, MRI & combined PET/CT. Cystoscopy and proctoscopy are only 
recommended if urinary bladder or rectal extension is suspected.
(13)
 
(AJCC) “American Joint Committee on Cancer” -8th edition- is the most 
widely used system for cancer cervix staging. Which is based on the tumor size 
(T), nodal involvement (N) & presence of distant metastasis (M).
(14)
 
The staging system suggested by FIGO is widely followed and correlate well 
with the prognosis.
(15)
 
Briefly stage I consists of disease limited to the cervix (IA: microscopic and 
IB: clinically apparent lesion). Stage II disease extends beyond the cervix reaching 
upper third of the vagina or parametrium. Stage III disease involvement of pelvic 
side wall or lower third of vagina including hydronephrosis or non-functioning 
kidney. Stage IV disease extends beyond the pelvis or involves the mucosa of the 
rectum or urinary bladder.
(15)
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Figure (1) –TNM & FIGO Staging of Cervical Cancer (AJCC Cancer Staging Manual. 
8
th
 edition 2018) 
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Figure (2) – Cervical Cancer Stages (AJCC Cancer Staging Manual. 8th edition 
2018). 
 
Table (1) – FIGO staging according to AJCC 8th edition(16) 
FIGO Stage 
 I: Carcinoma is strictly limited to the cervix. 
 -IA: Invasive carcinoma diagnosed microscopically. Stromal invasion is restricted to measured 
maximum depth of 5 mm & in horizontal spread not more than 7 mm. 
 -IA1: Stromal invasion is 3 mm or less in depth and in horizontal spread 7 mm or less. 
 -IA2: Stromal invasion more than 3 mm and not more than 5 mm in depth and in horizontal 
spread less than or equal 7 mm. 
 -IB: Visible lesions clinically confined to the cervix, or microscopic lesion greater than stage IA. 
 -IB1: Lesions are less than or equal 4 cm in size clinically in greatest dimension. 
 -IB2: Lesions are more than 4cm in size clinically in greatest dimension.  
 II: Tumor extends beyond the cervix, but not extended to the lower third of vagina or onto the 
pelvic wall. 
 -IIA: Involvement of upper two-thirds of the vagina. Without invasion of parametrium. 
 -IIA1: Lesion is visible clinically but in greatest dimension is less than or equal 4 cm in size. 
 -IIA2: Lesion is visible clinically and size in greatest dimension is more than 4 cm. 
 -IIB: Parametrial invasion but not to the pelvic side wall. 
 III: Tumor involves the lower 1/3 of the vagina OR tumor has extended to the pelvic side wall.  
 -IIIA: Involvement of the lower vagina without extension to pelvic side wall. 
 -IIIB: Pelvic extension, or hydronephrosis/non-functioning kidney. 
 IVA: Carcinoma invades mucosa of the rectum or the urinary bladder or extends beyond true 
pelvis 
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Pelvic examination under anesthesia (EUA) should be carried out for 
cervical cancer patients who presented with a clinically visible lesion, after 
obtaining a careful clinical history & performing a general physical examination 
for them. Pelvic examination under anesthesia should include inspection of the 
external genitalia, vagina, uterine cervix, rectal examination & bimanual palpation 
of the pelvis. Pelvic examination under anesthesia is widely accepted component in 
the clinical staging & evaluation of patients in order to provide a pain free 
examination that allows a clearer assessment of parametrial or sidewall tumor 
extension.
(17)
 
Speculum examination and thorough vaginal & rectal examination will give 
the exact clinical staging. Lesions may appear as exophytic or endophytic growth, 
as a polypoid mass, papillary tissue, or barrel shaped cervix, as a cervical 
ulceration or granular mass, or as necrotic tissue with purulent or bloody 
discharge.
(18) 
 
A significant number of doctors prefer CT for the evaluation of cancer 
patients, because of its wide availability.
(19)
 
Currently, in cancer cervix cases, MRΙ is used primarily for the evaluation of 
cancer morphology & local extent; it accurately evaluates cancer features of a 
significant prognostic value, like size, endo-cervical growth, parametrial invasion 
and pelvic side wall or adjacent organ involvement (urinary bladder, rectum). 
Reported MRI accuracy values for determining cancer stage (operable versus 
advanced disease) range from 75 to 96 percent.
(20)
 
Hybrid imaging (PET-MRI or PET-CT) is better than conventional cross- 
sectional methods for the identification of metastatic LNs, with excellent 
diagnostic accuracy, ranging from 85 to 99 percent.
(21)
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7. Pathological Types 
 
a) Cervical Intraepithelial Neoplasia (CIN): 
Intraepithelial changes begins with minimal atypia and progresses through 
stages of greater intraepithelial abnormalities in conformity with invasive 
squamous cell carcinoma. The phrases CIN, dysplasia, carcinoma in situ (CIS) 
and squamous intraepithelial lesion (SIL) could be used interchangeably.
(22)
 
CIN is usually a disease of meta-plastic squamous epithelium within the 
transformation zone. The usual process by which cervical squamous epithelium 
matures is disturbed in Cervical Intraepithelial Neoplasia, as proved 
morphologically by modifications within nuclear features, cellularity, polarity, 
differentiation, and mitotic activity. CIN 3 is synonymous with severe dysplasia 
and carcinoma in situ.
(22)
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Figure (3) Sequence of histological changes from CIN 1 to CIN 3.
(22)
 
When Cervical Intraepithelial Neoplasia is detected, colposcopy, along side 
a Schiller test, delineates the extent of the lesion suggests areas to be biopsied. 
Diagnostic endo-cervical curettage also can help in figuring out the extent of 
endo-cervical involvement. Females with CIN 1 are regularly observed 
conservatively (i.e. close follow-up with repeated Pap smears). High grade 
lesions are treated consistent with the extent of disease. Loop electrosurgical 
eradication process (LEEP), cervical conization (removal of a cone of tissue 
round the external os), laser ablation, electro-coagulation diathermy, 
cryosurgery, & hardly ever hysterectomy could also be done.
(22)
 
 
b) Microinvasive squamous cell carcinoma: 
The earliest invasive changes (early stromal invasion or ESI) show up as 
small irregular epithelial buds arising from the bottom of CIN 3 lesions. These 
tiny (b1 mm) tongues of neoplastic epithelial cells don't have an effect on the 
prognosis of CIN 3 lesions, so both are often treated in a similar fashion with 
conservative surgery. Within the 2009 FIGO classification, ESI was trimmed 
from stage IA1. Some oncologists moreover confine micro-invasive carcinoma 
to tumors without lympho-vascular invasion (LVI). Stage IA2 tumors are 
associated with lymph node metastases in around 8 percent of cases, Though 
those that invade ≤ 3 mm (stage IA1) have only a 1 - 2 percent risk of lymph 
node metastases. Conization or simple hysterectomy generally cures micro-
invasive cancers < 3 mm deep.
(22)
 
 
c) Invasive squamous cell carcinoma: 
Early stages of cervical cancer are frequently poorly defined lesions or 
exophytic and nodular masses. If the tumor is in the endo-cervical canal, it‟s 
often an endophytic mass, which will invade the cervical stroma and cause 
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diffuse cervical enlargement. Most tumors are non-keratinizing, have solid nests 
of huge malignant squamous cells and no more than individual cell 
keratinization. Most remaining cancers show nests of keratinized cells within 
concentric whorls, therefore known as keratin pearls. Cancer cervix spreads by 
direct extension or through lymphatic vessels & only rarely through blood 
vessels. Local extension into surrounding tissues (parametrium) leads to ureteral 
compression (Stage IIIB). The corresponding clinical problems are 
hydronephrosis, hydroureter, and renal failure due to ureteric obstruction which 
is that the commonest explanation for death (50 % of patients). Urinary bladder 
or rectal invasion (Stage IVA) may cause fistula formation. Metastases to 
regional LNs involve para-cervical, external iliac, and hypogastric nodes. 
However, tumor spread are fairly slow, considering the fact that since the typical 
age for patients with CIN 3 is 35 - 40 years, for stage IA carcinoma, 43 years, & 
for stage IV, 57 years.
(23)
 
 
d) Verrucous carcinoma: 
A variant of a very well differentiated squamous cell carcinoma that is 
characterized by   having a tendency to recur locally but not to metastasize. 
Mitotic activity is extremely low. It may be difficult to differentiate verrucous 
carcinoma from a giant condyloma with cytologic atypia or from a well 
differentiated invasive squamous carcinoma. Microscopically, verrucous 
carcinoma is exophytic, with an undulating, hyperkeratotic surface, the deep 
margin is composed of huge, bulbous masses that invade along a wide front in a 
pushing fashion.
(24)
 
 
e) Endocervical adenocarcinoma: 
Adeno-carcinoma in situ generally arises within the squamo-columnar 
junction and extends into the endo-cervical canal. Associated high-grade 
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squamous cell CIN presents in 40% of cases of AIS. Invasive aden-ocarcinoma 
commonly takes place as a polypoid or papillary mass.
(22)
 
 
f) Other rare pathological types: 
- Adeno-squamous carcinoma: represents about 2 percent -5 percent of 
cervical cancer & consists of intermingled epithelial cell cores with 
squamous features & glandular structures. The squamous component is 
frequently non keratinizing.
(25)
 
- Basaloid carcinoma or adenoid basal carcinoma: a very rare tumor 
which is characterized by nests or cords of small basaloid cells, prominent 
peripheral palisading of cells in the tumor nests, no significant stromal 
reaction or capillary space invasion, and an infiltrating growth pattern. 
Also characterized by its slow growth pattern with limited local 
invasiveness & low probability of LNs metastases.
(22)
 
- Adenoid cystic carcinoma: a rare variant of cervical adenocarcinoma 
represents about less than 1percent. It is composed of nests and nodules of 
small carcinoma cells with a few characteristic cribriform patterns. It is 
locally aggressive with a high probability to metastasize.
(26)
 
- Clear cell carcinoma: represents about 2 percent of cervical carcinomas. 
These tumors are submucosal, composed of clear cells & may grow in a 
tubular, glandular, papillary, or solid pattern. They appear at any age, with 
one third occurring in females younger than 30 years of age.
(27)
 
- Small cell carcinoma: is also a rare type of cervical cancer which is 
characterized by nuclear molding, absence of nucleoli, cell necrosis, and 
high mitotic activity. One third to one half stain positively for 
neuroendocrine markers like chromogranin, synaptophysin, somatostatin 
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or serotonin. Lympho-vascular invasion is significantly common in small 
cell carcinomas HPV 18 has been detected in most of these tumors.
(28)
 
- Malignant lymphoma: can be 1ry or 2ry in the cervix, and treated as 
other lymphomas.
(29)
 
 
8. Prognostic and Predictive factors 
a) Patient Related Factors: 
- Age: Is not a prognostic factor for cervical cancer as suggested by some 
reports, However some authors reported decreased survival in females 
younger than 35 or 40 years, In contrast, 2 European studies noted improved 
outcome for younger patients.
(30) 
 
- Socio-Economical, Racial and Regional Factors: Patients with lower 
socioeconomic status may present at advanced stages & may often not have 
the capacity to bear the cost of the standard of care.
(31)
 
- Anemia and Tumor Hypoxia: Anemia is common in cancer patients. Lower 
pre-treatment hemoglobin (Hb) level or anemia before treatment has been 
reported as an independent prognostic factor for poor prognosis in locally 
advanced cervical cancer (LACC).
(32)
 
- Medical Co-Morbidities: Co-morbid as diabetes, hypertension & 
cardiopulmonary diseases may lead to higher risk of mortality often by 
themselves. Uncontrolled medical conditions compromise the patient‟s 
likelihood of tolerating the concurrent chemo-radiotherapy  (CCRT) 
course.
(33)
 
- Human immunodeficiency virus (HIV) status: Women who are +ve for 
HIV have more aggressive and advanced sickness and a worse prognosis.
(34)
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b) Tumor Factors: 
- HPV Subtype: HPV 18 DNA has been determined to be an independent 
unfavorable molecular prognostic factor. Two research proved a worse 
outcome when HPV 18 was identified in cancer cervix patients undergoing 
radical hysterectomy and pelvic lymphadenectomy.
(35)
 
- Histology: A few retrospective studies showed a worse outcome for patients 
with adenocarcinoma, with a noted tendency for distant metastasis, when 
compared with those with squamous pathology. Suggesting that any 
adenomatous differentiation may confer a bad prognosis.
(36)
 
- Grade of Differentiation: Tumor grade is a prognostic factor for squamous 
cervical cancer, particularly early-stage disease. Higher tumor grade is 
associated with decreased survival. Routine evaluation of tumor grade with 
synoptic description is therefore highly recommended in daily practice
(37)
. 
Advanced stage along with poor histopathological differentiation influences 
the aggressiveness of the tumor responsible for distant relapse.
(38) 
 
- Staging: The Gynecologic Oncology Group (GOG) reported during a large 
surgico-pathological staging study on cases with clinical stage IB, that the 
factors which near prominently expected for metastases to lymph node and a 
reduction in disease-free survival when capillary-lymphatic space involved by 
cancer, large tumor size, & increasing depth of stromal infiltration, with the 
last being the most significant and reproducible.
(39)
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Table (2) – survival rates for cervical cancer
(40)
 
Stage 5-year survival rate 
Stage 0 93 percent 
Stage IA 93 percent 
Stage IB 80 percent 
Stage IIA 63 percent 
Stage IIB 58 percent 
Stage IIIA 35 percent 
Stage IIIB 32 percent 
Stage IVA 16 percent 
Stage IVB 15 percent 
 
- Nodal Status: LN involvement is considered as the single most significant 
determinant of adverse prognosis, even more than FIGO stage.
(41)
 
 
c) Biochemical markers: 
- Squamous cell carcinoma antigen (SCC Ag): Pretreatment (SCC Ag) has 
shown value as a predictor of lymph node involvement and treatment 
outcome. Also Post treatment measurements are predictive of relapse free 
survival. If (SCC Ag) was more than 30ng/mL at diagnosis there was 
significant lymph node involvement. The most significant of their finding was 
that the progression free survival (PFS) was significantly better in patients 
having normal levels of (SCC Ag) after concurrent chemo-radiotherapy in 
comparison to those in whom (SCC Ag) levels failed to normalize.
(42-43)
 
- Epidermal Growth Factor (EGFR): (EGFR) is over expressed in 50 to70 
percent of cervical squamous cell carcinoma, with lower expression among 
adeno & adeno-squamous carcinomas (44). Over expression of (EGFR) 
membrane staining was associated with an increase in radio resistance. The 
cytoplasmic staining of phosphorylated (EGFR) “the activated form” & the 
membrane staining of EGFR are both independent factors predictive of poor 
response to concurrent chemo-radiotherapy.
(45)
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- Carcino-embyrionc antigen(CEA): Prior to the discovery of SCC Ag, the 
foremost repeatedly measured tumor marker in cancer cervix was (CEA). Pre-
treatment (CEA) >10ng/mL is taken into consideration a risk factor for 
relapse after concurrent chemo-radiotherapy.
(46)
 
- CA-125: Pre-treatment CA-125 is high in 20 - 75 % of cases with cervical 
adeno-carcinomas, & that is often related to increased risk of lymph node 
metastasis & an overall poor outcome. Elevated CA-125 post treatment could 
possibly indicate recurrence of cervical adeno-carcinoma.
(47)
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9. Overview of Treatment 
A. Prophylactic: 
1. Avoid the risk factors: (Primary prevention) 
- HPV vaccine (FDA approved 2006). 
- Avoid early sexual exposure: especially with multiple / uncircumcised 
partners. 
- Use of condom. 
- Limitation of cigerate smoking. 
- Special care for immunocompromised patients. 
- Hysterectomy better to be total & not subtotal.(48-49) 
2. Proper treatment of the risk factors: (Secondary prevention) 
- Early detection of CIN by regular Pap smears for asymptomatic high risk 
patients. 
- Treatment of CIN: lesions by ablation or excision. 
- Strict follow up:  by colposcopy & smear for all treated cases.(50-51) 
 
B. Curative: 
 local/locoregional disease: Common types of treatments include 
 Surgery 
 Radiotherapy 
 Chemotherapy (chemo) 
 Targeted therapy 
Some cases may need more than one kind of treatment. For early stages of 
cervical cancer, either surgical operation or radiotherapy combined with 
chemotherapy might be used. For late stages, radiotherapy combined with 
chemotherapy is mainly the treatment of choice. Chemotherapy is mostly used 
to treat advanced cervical cancer.
(52)
  
28 
 
Specialists on cervical cancer treatment team may include; a gynecologist, 
a gynecologic oncologist, a radiation oncologist, & a medical oncologist. Other 
specialists might be part of the treatment team including physician assistants, 
nurse practitioners, nurses, psychologists, rehabilitation specialists, social 
workers, & other health professionals.
(52)
 
The main therapy of early stage cancer cervix is either surgery or 
radiotherapy. Surgery is typically done for small lesions & for the early stages of 
cervical cancer, like stage IA, IB1, & selected IIA1.
(53)
 
 
Treatment alternatives for cervical cancer 
 
Stage of cancer cervix is the most important factor in choosing of 
treatment, but other elements can also affect on choosing of treatment, as the 
type of tumor (squamous cell carcinoma or adenocarcinoma), the exact position 
of the tumor in the cervix, age of the patient and overall health, and whether she 
wants to keep her fertility or not.
(10)
 
- Stage 0 (Carcinoma in situ) “CIS”:  
(AJCC) “American Joint Committee on Cancer” staging system had classified 
carcinoma in situ as the earliest type of cancer cervix & medical doctors 
usually consider it as a pre cancer. That is due to the cancer cells within CIS 
present only within the superficial layer of the cervix, and don‟t grow into 
deeper layers. All patients with CIS are often cured with the proper treatment. 
However, pre-cancerous changes can sometimes come back within the cervix 
or vagina, so it's vital to closely observe patient after therapy. This consists of 
follow up with regular Pap tests and with colposcopy in some cases.
(10)
 
 
 Treatment alternatives for squamous cell carcinoma in situ: 
- Cryosurgery: It is a relatively simple procedure that takes around 15 minutes 
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and is performed as an outpatient procedure. It eliminates precancerous 
lesions on the cervix by freezing
(55)
. Cryotherapy is a highly effective 
treatment option for the small and superficial lesions, but for larger and 
deeper lesions the cure rate < 80 percent. Since the cervical area has very few 
nerve endings, therefore cryosurgery is generally associated with mild 
cramping and/or pain. So, it can be performed without anesthesia. But the 
absence of histo-pathological specimen for further evaluation of the extent of 
the disease and margins status is considered an important disadvantage of 
cryotherapy.
(56)
 
- Laser surgery: A focused laser beam is directed through the vagina to burn 
off abnormal cells or to get rid of a little piece of tissue and send to the histo-
pathology for tests. This can be performed in a doctor‟s clinic and is done 
with local anesthesia.
(10)
 
- Loop electrosurgical excision procedure (LEEP): It is the use of a thin 
heated wire for the removal of abnormal areas from the cervix. It needs an 
electrosurgical unit which produces a steady low voltage and transfers it to the 
wire loop device that is used to remove the abnormal tissue. The removed 
tissues should be sent for the examination to assess the extent of the lesion. So 
LEEP serves a double purpose, it treats the lesion and at the same time 
produces a specimen for histo-pathological examination. The procedure can 
be done under local anesthesia in an outpatient clinic. It is successful in 
eliminating pre-cancer in > 90 percent of cases. Treatment failure (i.e. 
persistent lesions at 6 or 12 months of follow up) is seen in < 10 percent of 
patients. 
(57)
 
- Cold knife conization: It is the removal of a cone shaped volume of cervical 
tissue including portions of the ecto-cervix & endo-cervix.  Conization is 
recommended in cases of dysplasia when outpatient treatment isn't accessible 
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or feasible & to exclude invasive carcinoma. It is an extensive operation 
involving removal of a large area of the cervix with a scalpel, & is often done 
under general or regional (spinal/epidural) anesthesia. It takes around 30 
minutes. Cold knife conization should be reserved for cases that can't be 
resolved with cryotherapy or LEEP excision due to possible side effects. The 
extent of the conization will depend on the size of the lesion and the 
probability of finding invasive cancer. The patient's desire to have a child 
must be considered, as conization may lead to cervical stenosis or 
incompetence in few females. The cone specimen is sent to lab for 
pathological diagnosis and to ensure complete removal of the abnormal 
tissue.
(56)
 
- Simple (total) hysterectomy: In simple hysterectomy the cervix and the body 
of the uterus are removed but the parametrium & uterosacral ligament are 
preserved. Also the vagina and the pelvic lymph nodes aren't removed. 
Ovaries & fallopian tubes are kept in place except if there is another cause to 
remove them.
(56)
 
 
 Treatment alternatives for adenocarcinoma in situ include: 
- Hysterectomy: The same as in SCC. 
- Cone biopsy: It is a possible option for females who wish to have children. 
The edges of the cone specimen must not have cancer cells & the patient must 
be closely monitored after treatment. Once the woman has no desire to 
reproduce, a hysterectomy is recommended.
(56)
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a) Surgery for invasive cervical cancer 
Many females with cancer cervix will have some form of surgery. First 
surgery is often used to diagnosis cervical cancer. Second it helps to know the 
extent of the cancer. Also it helps in therapy, especially for earlier stages. Several 
types of surgery may be used in treatment of cervical cancer, although a number of 
these destroy cervical tissue (with a laser or with cold) instead of removing it.
(52)
 
Definitive surgical management is feasible only in early stages of the 
disease, such as stages IA, IB1, and IIA1, when the vaginal involvement does not 
extend beyond 2 cm.
(58)
 
The extent of surgery will be managed according to the tumor stage, the age 
of the patient & co-morbidities. The patient's desires regarding fertility and 
management options need to be considered for example: 
1. In Stage IA1:  
Treatment for this stage relies upon whether or not patient wants to maintain 
fertility & whether the cancer has spread to blood or lymph vessels or not, which 
is termed lympho-vascular invasion.
(52)
 
- Fertility sparing: For cases who need preservation of fertility, cone biopsy ± 
pelvic LNs dissection is required.
(59)
 For cases with clear margins after cone 
biopsy, if fertility preservation is desired observation could also be a choice. 
For cases with positive margins after cone biopsy, options are either a radical 
hysterectomy or repeat the cone biopsy.
(60) 
For cases with stage IA1 disease 
with lympho-vascular invasion, radical hysterectomy and pelvic LNs 
dissection is suggested ± para-aortic LNs sampling.
(61) 
 
- Non fertility sparing: A simple hysterectomy could also be a choice if 
cervical cancer shows no lympho-vascular invasion. If tumor has grown 
within blood or lymph vessels, removal of the pelvic lymph nodes is need 
beside radical hysterectomy.
(62)
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2. In stage IA2 disease: 
Local excision can be offered to preserve fertility or extra-fascial hysterectomy. 
But there is a risk of pelvic lymph node invasion of about 5 percent & bilateral 
pelvic lymph node dissection is usually recommended.
(62)
 
- Radical trachelectomy (cervicectomy): It is the treatment of choice in 
females with early stage cancer cervix desiring to preserve fertility. Radical 
trachelectomy can be done with a vaginal, abdominal or laparoscopic/robotic 
approach.
(63) 
Intra-operative and postoperative complication rates are identical 
to radical hysterectomy. About 15 percent of patients develop cervical 
stenosis and this can lead to dysmenorrhoea or infection.
(64)
 
- Laparoscopic hysterectomy and lymph node dissection: It is offered to 
females not desiring to retain their fertility. The presence of +ve lymph nodes 
indicates the need for adjuvant chemo-radiotherapy.
(62)
 
3. Stages IB and IIA cervical cancer: 
It can be cured by radical surgery including pelvic lymph node dissection or 
radiotherapy. The two options are equally effective but differ in terms of 
morbidity and type of complications.
(65)
 
- Radical (Wertheim's) hysterectomy: This aims to provide definitive 
treatment for invasive & early metastatic cervical cancer. It involves excision 
of the primary tumor with a one cm margin of healthy tissue and resection of 
the main pelvic lymph node areas. It may involve removal of the upper third 
of the vagina & utero-vesical & utero-sacral ligaments. Urinary bladder 
function returns slowly and chronic retention may occur. Sometimes painful 
lymphocytes develop and their drainage may be required.
(65)
 
- Anterior, posterior or total pelvic exenteration: Involve removal of pelvic 
adnexae with removal of the urinary bladder and/or recto-sigmoid, with 
possible creation of one or two stoma. The patient should be relatively fit and 
33 
 
can hold out very destructive surgery.
(65)
 
 
 Neoadjuvant chemotherapy to surgery: The purpose for the use of 
Neoadjuvant chemotherapy (NACT): (i) reduction of the primary tumor size, 
allowing operability; (ii) eradication of micro-metastatic disease; and (iii) 
potential increase in tumor vascularization and reduction of the number of 
hypoxic cells.
(66-67) 
In a meta-analysis, NACT followed by radical surgery 
showed a significant 35 percent reduce in the risk of death compared with 
radiotherapy alone, with an absolute improvement of 14% in survival at 5 years, 
increasing from 50% to 64%.
(68)
 
 Adjuvant treatment: Women with risk factors on the pathology specimen 
should receive adjuvant therapy following hysterectomy. Two classes of risk are 
defined: Major risk factors and Minor risk factors. 
o Major RF: 
- Status of resection margins. 
- Status of parametria and vaginal cuff. 
- Number and status of lymph nodes. 
o Minor RF “Sedli’s criteria”: 
- Lympho-vascular space invasion. 
- Size of the tumor (> 4 cm). 
- Stromal invasion/depth of the wall involved (> 1/3). 
 If women has one of major risk factors on the pathology specimen should 
receive adjuvant Concurrent Chemo & Radiotherapy following hysterectomy. 
 If she has No major risk factors but has 2 of 3 minor she should receive only 
adjuvant Radiotherapy alone (without chemotherapy). 
 The most commonly used regimen is weekly cisplatin 40 mg/m2.(69-70) 
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b) Radiotherapy (RT) for invasive cancer cervix 
 
 Radiotherapy uses radioactive particles or high energy x rays to damage 
cancer cells. Radiotherapy is also used for cancer cervix, for few stages of cancer 
cervix the preferred therapy is radiotherapy alone or surgery then followed by 
radiotherapy. For other stages, radiotherapy & chemotherapy given together & 
that‟s called concurrent chemo-radiation which is the preferred therapy. The 
chemotherapy helps the radiation to work better .Also radiotherapy may be used in 
treatment of metastatic cancers that have spread to other organs or tissues.
(52)
 
There are two types of radiotherapy usually used to treat cancer cervix which 
are external beam radiotherapy & brachytherapy.
(52)
 
 Radiotherapy is generally used for cervical cancer either as definitive 
therapy for cases with locally advanced cancer or for cases who are not fit for 
surgery, as adjuvant therapy following radical hysterectomy for cases who have 
one or more pathological risk factors for example: +ve lymph nodes, parametrial 
invasion, +ve surgical margins, large tumor size, deep stromal infiltration, and 
lympho-vascular invasion.
(52)
 
 A study review discovered insufficient evidence that hysterectomy with 
radiotherapy, with or without chemotherapy improves the survival of females with 
locally advanced cancer cervix who are treated with radiotherapy or chemo-
radiotherapy alone.
(71)
 
The combination of two consecutive stages of irradiation with different dose 
delivery techniques, i.e., external beam radiotherapy (EBRT) and intracavitary 
high-dose-rate brachy-therapy (HDR-BT) is called combined RT.
(72)
 
At the first stage of combined RT, the clinical tumor volume and regional 
lymph nodes are irradiated in total doses up to 44-50 Gy with fraction dose equal 
to 2 Gy depending on the widespread nature of the process. At the second stage of 
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the combined RT, the clinical tumor volume is irradiated in the mode of dose boost 
when the dose per fraction is increased to 6-7.5 Gy delivered in 4 or 5 fractions 
resulting in the total dose equal to 28-30 Gy. The goal of the total combined RT 
course is to achieve a total EQD2 dose equal to 90 Gy delivered to the clinical 
tumor volume in less than 50 days of treatment.
(73-74)
 
 
A. External beam radiotherapy: 
External beam radiotherapy (EBRT) may be routinely administered to 
cancer cervix female patients with stages IB2 - IVA aiming a curative intent. 
Females with stages IA - IB1 may also receive external beam treatment if they 
are inoperable or prefer to avoid surgery. Patients with stage IVB disease may 
receive palliative radiotherapy to the pelvis for selected indications for example, 
to relieve pain, stop vaginal bleeding, or relieve urethral obstruction from 
extrinsic compression. External beam radiotherapy covers the 1ry cervical 
tumor, treats any adjacent parametrial or utero-sacral, uterine, or vaginal 
extension, & most essential microscopic disease present in pelvic LNs.
(52)
 
The usage of CT based therapy planning & conformal blockage is taken 
into account the standard of care for external beam radiotherapy. MRI is that the 
superior imaging modality for identifying parametrial & soft tissue infiltration in 
cases with advanced cancers, PET imaging is beneficial to assist outline the 
nodal volume of coverage, in cases who aren‟t surgically staged.(52)  
Coverage regarding microscopic nodal disease requires a dose of about 45 
Gy of an EBRT (in fractionation of 1.8 - 2.0 Gy daily). Most of the patients who 
receive EBRT for cancer cervix, concurrent chemotherapy (either Cisplatin 
only, or Cisplatin with 5-fluorouracil) is given during EBRT.
(75)
 
Intensity modulated radiation therapy (IMRT) can help in reducing the 
dose to the bowel & other vital organs within the post hysterectomy setting & in 
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treating the para-aortic nodes. Also these methods are beneficial when excessive 
doses are desired to treat gross disease within regional LNs.
(75)
 
 
 Parametrial boost: This is optional; it is used in stage FIGO IIb patients & 
above (ie any patient with parametrial extension). The Dose required for 
parametrial boost is 5.4Gy in 3 daily fractions over 3 days. Parametrial boost 
is a debatable topic & must be assessed on a patient to patient basis. A 
retrospective study conducted to validate the practice of not treating clinically 
infiltrated parametrium by parametrial boost & to validate the adequacy of 
nodal boost in node positive patients regardless the status of parametrium. 
Results showed that cervical cancer with clinically infiltrated parametrium 
can be treated without parametrial boost.
(76)
 
 Complications of EBRT for cervical cancer: 
 Early: 
- Fatigue  
- Stomach upset  
- Diarrhea  
- Skin changes: because the radiation crosses via the skin to the tumor, it 
may affect the skin cells causing changes ranging from mild redness to 
sever peeling. Also the skin might release fluid which will cause 
infection thus the area exposed to radiotherapy must be cleaned & 
protected carefully. 
 Late: 
- The rate of major late side effects of radiotherapy for stages I & IIA 
cervical cancer ranges from 3-5 percent & for stages IIB & III between 
10-15 percent. Injury to the gastrointestinal tract usually appears within 
the 1st  2 years after therapy, while that of the urinary tract are seen more 
frequently 3-5 years after therapy.
(77)
 
- Anal incontinence is observed occasionally from the late side effects of 
radiation therapy. Study investigated radiotherapy effects on ano-rectal 
function using manometry in twenty four patients with cervical cancer 
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who had late radiation proctitis. These data were compared with those 
from 24 age-matched non-irradiated female volunteers. Regardless of the 
severity of proctitis symptoms, 75 percent of irradiated patients exhibited 
abnormal manometric parameters for motor or sensory functions. 
Radiation damage to the external sphincter muscle & to nerves was 
considered to be an essential cause of motor dysfunction.
(78)
 
- Ureteral stricture was found in 2.5 % of 1,784 cases with stage IB 
cervical cancer treated with radiation. Flank pain and urinary tract 
infection were the commonest presenting symptoms. Ureteral stricture in 
5 cases was complicated by a vesico-vaginal fistula.
(78)
 
- Urinary tract infections development. Study collected two hundred and 
sixth-teen urine samples from thirty six patients receiving pelvic 
irradiation, twelve of them had urinary tract infection. The most common 
organisms isolated were Escherichia coli, & Enterococcus species. 
Proper urine bacterial studies & cultures are indicated in patients 
suspected of having superimposed urinary tract infection during the 
course of radiotherapy.
(80)
 
- Radiation to the pelvis can irritate the urinary bladder which is called 
radiation cystitis causing discomfort & a usual urge to urinate. Study 
identified 116 of 1,784 patients (6.5 %) with stage IB cervical carcinoma 
treated with radiotherapy in whom hemorrhagic cystitis developed, 23 % 
was grade 2 (repeated minor bleeding) & 18 % was grade 3 
(hospitalization required for medical management). The onset of 
hematuria median interval was 35.5 months. The risk of severe 
hematuria requiring surgical intervention was 1.4 % at ten years & 2.3 % 
at twenty years.
(81)
 
- Radiation can make the vulva & vagina more sensitive that may lead to 
vaginal pain & occasionally causes a discharge.
(75)
 
- Pelvic radiation can affect the ovaries that may lead to menstrual 
changes & even early menopause. Radiation causes ovarian failure with 
a cessation of menses over a six month - one year period after treatment. 
Radiation also causes uterine fibrosis in a dose dependent fashion.
(82)
 
- Low blood counts: such as anemia, leucopenia which increases the risks 
of serious infection.
(75)
 
 
38 
 
B. Brachytherapy: 
Brachytherapy is short wave radiation therapy delivered by the insertion of 
applicators into the uterus via the vagina. The American Brachytherapy Society 
indicates that brachytherapy should be considered an essential component of 
definitive radiotherapy treatment.
(83)
 
Brachytherapy or internal radiotherapy is putting a radiation source within 
or near the tumor. This kind of radiotherapy travels a brief distance. The sort of 
brachytherapy frequently used in therapy of cervical cancer is intracavitary 
brachytherapy. The radiation source is placed in a device into the vagina & may 
be into the cervix. And often additionally employed to external beam 
radiotherapy as a part of the most essential therapy for cervical cancer.
(84)
 
Brachytherapy is an essential part of definitive radiotherapy shown to 
improve Overall survival.
(84)
 
 Types of brachytherapy: High dose rate (HDR), Medium dose rate (MDR), 
pulsed dose rate (PDR), and Low dose rate (LDR) brachytherapy are 
considered equivalent in terms of outcome and complication risk when 
carefully applied and individualized based on the need of the patient and 
pertinent clinical history.
(85)
 
 Low-dose rate brachytherapy (LDR-BT) is fulfilled over some days. 
During these days, the treated person stays in a private room in the health 
center with devices holding the radioactive material within place. While the 
radiotherapy is being given, the health center staff will care for the patient, 
but also take precautions to minimize their own radiation exposure. (LDR) 
brachytherapy delivers radiation at a dose of 0.4-2 Gray (Gy)/hour.
(86)
 
 High-dose rate brachytherapy (HDR-BT) is performed as an outpatient 
over radioactive material is inserted for some minutes & then removed. The 
advantage of HDR therapy is that you simply don't need to stay for long 
periods of your time in the hospital. HDR brachytherapy delivers a dose 
more than12 Gy/hour.
(86)
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 Medium-dose rate brachytherapy (MDR-BT) is to deliver a dose of 2-12 
Gy/h, & it is not in common use. In those few cases in which it has been 
used, the treatment results have been rather poor compared with LDR or 
HDR treatments.
(86)
 
 Pulsed Dose Rate brachytherapy (PDR-BT) is a recent brachytherapy 
modality that combines physical advantages of high-dose-rate (HDR) 
technology (isodose optimization, planning flexibility and radiation safety) 
with radiobiological advantages of low-dose-rate (LDR) brachytherapy 
(repair advantages).
(86)
 
Outcomes after LDR and HDR brachytherapy have been compared in 
different number of retrospective, institutional studies as well as in 
prospective randomized trials that noted same survival outcomes for both.
(86)
 
A Cochrane review has recommended the use of high dose rate 
intracavity brachytherapy for all clinical stages of cervical cancer.
(86)
 
 
 Brachytherapy applicators: they are medical devices that guide the 
radioactive source to be near to the tumor for a therapy time. 
Brachytherapy is an essential component of definitive therapy for all 
cases with 1ry cervical cancer who aren't candidates for surgical treatment. 
This is often performed using an intra-cavitary approach, with an intrauterine 
tandem & vaginal colpostats. According to the patient anatomy & the tumor, 
the vaginal component of brachytherapy could be delivered using ovoids, 
ring, or cylinder (combined with the intrauterine tandem) in cases with an 
intact cervix. MRI imaging immediately preceding brachytherapy may be 
helpful in delineating residual tumor geometry. When combined with EBRT, 
brachytherapy is usually initiated for the therapy of the residual tumor. In 
early disease like, stage IA2, brachytherapy alone without EBRT may be an 
option.
(87)
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Since HDR contact therapy exhibits steep dose fall-off around the 
source, the role of the brachytherapy applicator is crucial: inappropriate 
placement of the source results in „„hot” and „„cold” spot in the dose 
distribution.
(88)
 
 
 Two applicator types: standard and 3D printed. 
- Standard applicators have a poor ability to comply to the patient anatomy 
variability & have big air gaps between the applicator and the skin 
standard.
(89)
 
 
 
Figure (4) –  Ring–tandem & ovoid–tandem “standard” applicators.(90) 
 
- 3D printed applicators by using 3D printers is a new technique that 
utilizes patient CT information to create an applicator that conforms to 
the curvature of the patients anatomy for treatment of various types of 
cancers. Applicators printed using acrylonitrile butadiene styrene (ABS) 
plastic. That would offer comparable dose distributions, reproducibility, 
and conformity with the patient leading to smaller air gaps between 
applicator and treatment site, and decrease the applicator errors. Also 
offer better patient conformity, reduced air gap, and convenience to both 
patient and therapist.
(88)
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Figure (5) –  3D printed vaginal applicator with catheter tunnels.(88) 
 
 
 Possible short-term side effects of brachytherapy:  
 The radiation with brachytherapy only travels a short distance so the main 
outcomes of the radiation are on the cervix & the walls of the vagina, 
including: 
- Vaginal irritation (commonest). It becomes red, sore & there may be a 
discharge. 
- Vulvar irritation 
- Pain and discomfort at the site of the applicator. 
- General feeling of fatigue 
- Short term urinary symptoms including urinary retention, pain on 
urination, incontinence and inability to urinate. 
 Brachytherapy may also cause many of the same outcomes as EBRT, for 
example diarrhea, nausea & low blood counts. 
 The side effects usually resolve within a few days following the completion 
of treatment. However, severe bleeding, pain and infection are side effects 
that require immediate medical attention. 
 Usually brachytherapy is given after EBRT before the outcomes can go 
away so it is difficult to know which type of radiotherapy is the cause of 
the complications.
(91-92) 
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c) Chemotherapy for cervical cancer  
 
Many patients with cervical cancer receive chemotherapy, either adjuvant, 
concurrent with radiation or palliative.
(93)
 
For few stages of cancer cervix, the preferred therapy is radiotherapy & 
chemotherapy given together which is called concurrent chemo-radiation. The 
chemotherapy helps the radiation work better.
(52)
 
 Choices for concurrent chemo-radiation include: 
- Cisplatin given weekly during radiation given intravenous (IV) about 4 
hours before the radiotherapy. 
- Cisplatin + 5-fluorouracil (5-FU) given every 4 weeks during radiotherapy. 
- Carboplatin has been added to the guidelines as a preferred radio-sensitizing 
agent for patients who are Cisplatin intolerant.
(52)
 
- Chemotherapy can be used for cancers that have spread to other organs & 
tissues. Also It can be helpful when cancer recurs after treatment with 
chemo-radiation.
(52)
 
 
 The chemotherapy drugs usually used to treat advanced cancer cervix: 
- Cisplatin. 
- Carboplatin. 
- Paclitaxel “Taxol”. 
- Topotecan. 
- Gemcitabine “Gemzar”. 
 
Combinations of these chemotherapy drugs are usually used. Others can be 
used also, for example, Ifosfamide “Ifex”, Docetaxel “Taxotere”, 5- fluorouracil 
“5-FU”, Mitomycin & Irinotecan “Camptosar”. Also Bevacizumab “Avastin” the 
targeted drug could be added to chemotherapy.
(52)
 
Chemotherapy is usually recommended for patients with recurrent disease or 
extra-pelvic metastases who aren‟t candidates for radiotherapy or surgery. Patients 
whose disease responds to chemotherapy may have relief from their symptoms. If 
Cisplatin was previously administrated as a radio-sensitizer, combination platinum 
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based regimens are favored over single agents in the metastatic cases which is 
based on few randomized phase III trials. But responses to chemotherapy are 
usually of short duration and survival is rarely increased.
(94-95)
 
Cisplatin has been considered the most efficient agent for metastatic cancer 
cervix.  Most patients who develop metastatic disease receive concurrent Cisplatin/ 
plus radiotherapy as primary therapy & may no longer be sensitive to single 
platinum based chemotherapy. Cisplatin based combination chemotherapy 
protocols like Cisplatin/Paclitaxel /Bevacizumab, Cisplatin/Paclitaxel & 
Cisplatin/Topotecan, have been widely investigated in clinical studies.
(94-95-96)
 
Study compared (Cisplatin/Paclitaxel) versus Cisplatin alone for metastatic, 
recurrent, or persistent cervical cancer. Females receiving the two drug 
combination had a higher response rate (36 percent versus 19 percent) and 
improved Progression free survival (4.8 months versus 2.8 months) compared to 
single agent Cisplatin, but no improvement was viewed in median survival. Also 
patients who responded to Cisplatin/Paclitaxel had a significant improvement in 
quality of life.
(95)
 
In Another study patients investigated for Cisplatin alone versus 
(Cisplatin/Topotecan) for recurrent or persistent cancer cervix. The single agent 
Cisplatin was shown to be inferior to Topotecan combination regimen with respect 
to overall response rate, Progression free survival, & median survival.
(94)
 
(FDA) “the Food and Drug Administration” has approved 
(Cisplatin/Topotecan) for advanced cancer cervix. But the (Cisplatin/Paclitaxel) or 
(Carboplatin/Paclitaxel) protocols are less toxic & easier to be used than protocol 
(Cisplatin/Topotecan).
(97)
 
Generally Cisplatin is considered as the most active agent and is usually 
recommended as a 1st line single agent chemotherapy choice for recurrent or 
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metastatic cancer cervix, reported response rates are about 20-30 percent with an 
occasional complete response (CR).
(98-99)
 
Overall survival (OS) with Cisplatin is about 6 - 9 months. Both Carboplatin 
& Paclitaxel have been reported to be tolerable and effective & are also possible 
1st line single agent chemotherapy. So palliation with single agents Cisplatin, 
Carboplatin, or Paclitaxel could be a reasonable strategy in cases with recurrent 
disease not candidate for surgery or radiotherapy.
(100)
 
 
 Targeted therapy for cervical cancer:  These are newer drugs that 
specifically target changes in cancer cells & nearby cells that help them 
grow. These work differently from standard chemotherapy drugs & usually 
have different complications. For an example, tumors must form new blood 
vessels to supply them by nourishment to grow. This process is named 
angiogenesis. Some drugs arrest this vessels growth & these drugs are 
known as angiogenesis inhibitors. 
-  Bevacizumab (Avastin®) is an angiogenesis inhibitor drug which could be 
used in treatment of advanced cancer cervix. It‟s a monoclonal antibody 
which targets vascular endothelial growth factor (VEGF), a protein that 
helps in formation of new blood vessels. This drug is usually used with 
chemotherapy for a period. And if the cancer responds, the chemotherapy 
may be stopped & Avastin given by itself till the cancer starts growing 
again.
(96)
 
-  Pazopanib is a potent selective multi targeted receptor (Tyrosine kinase 
inhibitors (TKI)s of VEGFR-1,VEGFR-2,VEGFR-3), that blocks tumor 
growth and inhibits angiogenesis.
(101)
 
-  Gefitinib is TKIs against endothelial growth factor receptor (EGFR), which 
have been evaluated as single agents in patients with cancer cervix.
(102)
 
-  Temsirolimus is a mTOR (is a key protein kinase controlling signal 
transduction from various growth factors and upstream proteins to the level 
of mRNA and ribosome with regulatory effect on cell cycle progression, 
cellular proliferation & growth) inhibitor used in patients with cancer 
cervix.
(103)
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 Advanced/metastatic disease: 
 Stages IIb-Iva: (parametrial extension up to lesions involving nearby organs 
such as the bladder and the rectum) 
- External beam radiotherapy & concurrent chemotherapy (cisplatin) with 
brachytherapy is the core treatment in patients with advanced cancer.
(104-105)
 
- The combination of 5-fluorouracil & cisplatin  has been used as concurrent 
chemotherapy also. They are both radiosensitisers & are associated with a 
longer period of disease remission and reduced disease progression.
(106)
 
 Stage IVb: (distant metastasis) 
- There is no standard treatment but it is mainly palliative with a 
multidisciplinary approach, including gynaecological surgeons, oncologists, 
a palliative care team, nurse specialists & occupational therapists. Optimal 
pain control should be readily achievable. Palliative doses of radiotherapy 
may be given to achieve reasonable bleeding control if this becomes a major 
issue.
(107)
 
 
 Recurrent cancer cervix: 
 Management is multidisciplinary and depends on the type of recurrence, mode 
of primary therapy & the woman‟s fitness. If there‟s local pelvic recurrence 
following primary therapy together with radiotherapy, the lady could also be 
appropriate for pelvic exenterative surgery. Exenterative surgery in carefully 
selected cases could provide a 5-year survival of 40-60 percent.
(108)
 
 The standard therapy is radiotherapy with or without platinum-based 
chemotherapy, if there‟s recurrence after surgery. The role of chemotherapy is 
mainly for palliation to relieve symptoms as well as to prolong survival.
(109)
 
 Radical hysterectomy & pelvic exenterative surgery involving partial resection 
of the bladder, bowel and/or ureter may be performed in carefully selected 
women with persistent disease following primary radiotherapy. The morbidity 
from such extensive surgery is high & only few women are suitable for this 
procedure; however, some may be cured & thus have a good quality of life.
(107)
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10. Techniques delivery of prescription dose (3DCRT, IMRT, 
VMAT) 
 
(3DCRT) “Three-dimensional conformal radiotherapy” is a method where 
the beams of radiation utilized in therapy are shaped to suit the cancer. Conformal 
radiotherapy uses the targeting information of CT image to focus exactly on the 
cancer while avoiding the healthy tissue. This made it feasible to use high levels of 
radiation in therapy, which are more effective in killing and shrinking cancers.
(110)
 
 
While 3DCRT planning & delivery approves for correct dose conformity to 
irregular shapes, there are still obstacles within the corrections which might be 
made. As its name implies, (IMRT) “intensity-modulated radiotherapy” allows the 
modulation of the intensity or fluency of every radiation beam, so every field 
might have certain or many areas regarding high-intensity radiation & some 
varieties of lower-intensity areas within a similar field, hence allowing higher 
control regarding the dose distribution within the target.
(111)
 
 
IMRT utilizes specific beam modifiers to differ or modulate the radiation 
intensity over the field of delivery. The aim is to control the beam hence that when 
the whole radiation delivery is taken into account, the dose conforms intently 
according to the cancer or target volume within the patient. IMRT can additionally 
utilizes more radiation beams of various sizes & various intensities to irradiate a 
cancer with precision & accuracy. The intensity of radiation of every portion of the 
beam is controlled, & the beam shape can alternate or multiple beams used during 
every treatment. The aim of IMRT is to shape the radiation dose to avoid or 
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minimize exposure of normal tissue & reduce the complications of therapy while 
delivering a therapeutic dose to the tumor.
(112)
 
 
(VMAT) “Volumetric arc therapy” is a sort of IMRT in which the therapy is 
delivered in certain or more dynamically modulated arcs. Because the gantry 
rotates, the MLCs move, giving a special aperture form for every angle of the 
gantry. The speed of rotation of the gantry & the LINAC dose rate could be 
modulated during therapy to give the desired delivered dose for every gantry angle. 
The standard of the planned dose distributions which may be achieved is such as 
those that can be done with other varieties of IMRT. The plan quality relies upon 
attainable modulation, which, in turn, relies upon the gantry speed, number of arcs, 
or both. The main advantage concerning VMAT is the whole therapy is often 
completed shortly. This advantage is important, so we anticipate that VMAT will 
be the IMRT delivery technique of choice for many treatments.
(113-114) 
 
11. VMAT boost for 2nd stage of RTH replacing brachytherapy 
 
The second stage of combined RT is usually implemented using 
intracavitary HDR-BT based on gamma-emitting radionuclides 60-Cobalt or 192-
Iridium.
(73)
 
The advantage of Brachytherapy over external beam is the possibility of 
delivering a high dose to a clinical tumor volume with a relatively low dose load 
on organs at risk (bladder and rectum). However, Brachytherapy has several 
significant drawbacks compared with external beam radiotherapy (EBRT). The 
main one is the substantial heterogeneity of the coverage of the clinical target 
volume, where doses in the range from 90% to 300% of the prescribed dose are 
delivered.
(74)
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Brachytherapy is also a less comfortable procedure for patients because they 
experience painful sensations when inserting applicators into the uterine cavity, 
which sometimes requires anesthesia.
(115)
 
On the other hand, with Brachytherapy, no additional margin from the 
clinical tumor volume (CTV) is required, which should consider the inaccuracy of 
dose delivery from fraction to fraction, i.e., creating a planned target volume 
(PTV), which is mandatory for EBRT. Because irradiation occurs from inside and 
not from the outside, in the case of movement of the organ with the implant 
inserted, the implant will move along with the organ.
(74-116)
 
Volumetric arc therapy (VMAT) shows great potential for producing highly 
conformal doses to treatment volumes while sparing organs at risk (OARs). 
VMAT was successful in duplicating the high-dose volumes (200%-75%) of the 
brachytherapy treatment plans, as well as delivering a homogenous dose 
distribution of 6 Gy to the PTV. VMAT could potentially be an alternative option 
for duplicating traditional brachytherapy dose distributions for patients in need of 
brachytherapy who are unable to undergo the treatment modality.
(117)
 
The first investigations devoted to the study of the possibility of replacing 
Brachytherapy with external beam radiotherapy (EBRT) during the second stage of 
combined radiotherapy started in 2012. The goal of such investigations was to 
change Brachytherapy with external beam radiotherapy (EBRT) in 
hypofractionation mode for patients for whom Brachytherapy was not possible for 
various reasons.
(118)
 
Also Brachytherapy (BT) is a major component in radiotherapy of locally 
advanced cancer cervix, but it is impractical for some patients due to medical, 
ethical or religious causes. For these patients, only external beam radiotherapy 
(EBRT) is used, so this study aiming to carry out a dosimetric and radiobiological 
planning of the replacement of traditional combined radiation therapy [3D 
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conformal radiotherapy (3D-CRT) + high-dose-rate brachy-therapy (HDR-BT)] by 
combinations of [(3D-CRT) + (VMAT)] or [(VMAT) + (VMAT)] while 
preserving the value of the total dose delivered and the number of fractions to 
detect the best technique among russian patients at Tomsk Regional Oncology 
Center, Tomsk Polytechnic University. This will be aid to improve the radiation 
planning and delivery to cervical cancer patients in the Russian & Egyptian 
population. 
 
12. Patient positioning and immobilization Devices 
 
Variation in the patient positioning is major problem during radiotherapy for 
pelvic malignancies. Higher patient setup errors will compel Radiation oncologist 
to give a larger planning target volume (PTV) margins, i.e. irradiate more normal 
tissues. Smaller PTV margins may lead to potential geographic miss of the target 
volume and, hence, may lead to recurrence.
(119)
 
All the patients were positioned in a supine position with hands above the 
head or akimbo on the chest based on the patient comfort. Immobilization 
objectives to supply reproducible patient positioning with little patient movement, 
also patient comfort should be considered; there should keep a balance between the 
2 aims. Various immobilization devices to be used on the linac couch are available; 
these encompass:  
 Vacuum bag cushion(VBC): 
- Whole body VBCs are nylon mattress filled with tiny polyurethane beads. 
Patient is made to lie down in a supine position. A comfortable cradle is 
formed around to conform to the body contours of the patient by using a 
vacuum pump for 10 min. After the VBC achieved the desirable firm 
consistency, the self-sealing quick release valve was used to seal the 
mattress. The laser marks are placed on the VBC, corresponding to indexer 
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and on the patient‟s body for daily setup reproducibility. These minimize 
pelvic tilt, which may occur after the 1st few fractions when the person tend 
to be more relaxed during therapy.
(120-121)
 
 
 
Figure (6) – vacuum bag cushion
(121)
 
 Knee & ankle supports: 
- Usually utilize in combination with other fixation devices to confirm 
reproducible leg position, which, by the way, stabilizes setup in the trunk 
region.
(120)
 
 
Figure (7) – Knee & ankle supports(120) 
 
51 
 
 External & Internal Markers: 
- Cases are usually aligned to external markers either positioned on the top 
cast or located at patient tattoo position. External marker positions are 
commonly defined at CT simulation time, whereby external fiducial markers 
are positioned with regard to isocenter. Unfortunately, there‟s internal organ 
mobility so external markers can at the best only guide the initial therapy 
setup. While some structures like the pelvic LNs may follow the bony 
anatomy quite nicely.
(120)
 
- Consider using vaginal, anal, & cervical markers to delineate normal tissue 
structures.
(122)
 
13. Equipment 
 Elekta Synergy accelerator: 
- Elekta Synergy accelerator is produced by Elekta (Elekta Oncology Systems, 
Crawley, UK). A few hundred of such accelerators are now used clinically. 
The Elekta Synergy can deliver photon and electron beams. The accelerator 
may be used to irradiate complex targets in 3D conformal and Intensity 
Modulation mode. Before first clinical use according to international 
recommendations the acceptance and commissioning tests have to be 
performed. Later the quality control tests have to be performed regularly. 
The Synergy is reportedly an advanced digital linear accelerator and first 
platform to enable clinicians to image and treat patients simultaneously. The 
combination of high-resolution imaging, taken in 3D and at the time of 
treatment, combined with workflow solutions developed to be applicable on 
a routine basis, is described as „4D Adaptive,‟ said Elekta.(123) 
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Figure (8) – Elekta synergy linear accelerator(123) 
 
 Multileaf collimators (MLCs): 
- Multileaf collimator is becoming the main tool for beam shaping on the 
linear accelerator. It is a simple and useful system in the preparation and 
performance of radiotherapy treatment. Multileaf collimators are reliable, as 
their manufacturers developed various mechanisms for their precision, 
control and reliability, together with reduction of leakage and transmission 
of radiation between and through the leaves. Multileaf collimator is known 
today as a very useful clinical system for simple field shaping, but its use is 
getting even more important in dynamic radiotherapy, with the leaves 
moving during irradiation. This enables a precise dose delivery on any part 
of a treated volume. Intensity modulated radiotherapy (IMRT), the therapy 
of the future, is based on the dynamic use of MLCs.
(124)
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Figure (9) – Multileaf Collimator (124) 
 
14. Treatment planning system 
 Monaco: 
- Monaco is a comprehensive treatment planning solution for 3D, IMRT, 
VMAT and stereotactic techniques that uses the gold-standard Monte Carlo 
dose calculation algorithm to deliver highly accurate dose distributions. With 
a suite of optimization tools, the Monaco software is designed to generate 
plans that spare as much healthy tissue as possible, while maximizing dose 
to the target.
(125)
 
- The Monaco Treatment Planning System supported a virtual energy fluency 
model of the photon beam tip elements of the linac & a dose count machine 
done together with Monte Carlo  algorithm X-Ray Voxel MC (XVMC), has 
been examined before being put into clinical use. An Elekta Synergy 
together with 6 MV was characterised the use of routine equipment. After 
the machine‟s model was installed, a group of functionality, geometric, 
dosimetric & information transfer tests have been performed. The dosimetric 
tests included dose calculations in water, heterogeneous phantoms and 
Intensity Modulated Radiotherapy (IMRT) verifications. Data transfer 
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checks have been run for each imaging device, TPS and the electronic 
medical history connected to Monaco.
(126)
 
 
15. MultiSource HDR & HDRplus for brachytherapy 
 
 MultiSource HDR:  
- The MultiSource radiation unit is a remote-controlled automatic afterloading 
device for gamma radiation and can be used with a Co-60 or an Ir-192 
source. It is used for interstitial, intracavitary, intraluminal and intraoperative 
brachytherapy. Radiation of the skin surface is also possible.
(127)
 
- The radiation unit must only be used by trained qualified staff under the 
instruction of a specialist doctor who is familiar with the kind of therapy. 
The pertinent accident prevention regulations, radiation protection 
regulations, occupational health regulations and other generally accepted 
occupational health and safety regulations must be needed. Proper use 
covers working with the MultiSource radiation unit for measuring and 
testing purposes in compliance with the safety regulations stated above.
(127)
 
 
 
Figure (10) – MultiSource HDR
(127)
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 HDRplus: 
- The HDRplus software is a radiation therapy planning system to perform 
high dose rate and pulse dose rate brachytherapy planning in combination 
with the appropriate afterloader device. With this software package, you may 
perform studies based on one or two co-registered image sequences, 
isocentric orthogonal x-ray films, isocentric semi-orthogonal x-ray films, 
non-isocentric x-ray films using a Reco-Box or even without images. 
- You first will need to enter general data on the patient and the study. 
- The images must be loaded into to the study by using one of several methods 
available for image sequences and orthogonal image plans (scanner, video 
frame grabber, network supporting DICOM file transfer, or image files on 
data carrier, i.e. CD, DVD, memory stick, etc.), 
- Then reconstructing the applicators, for image sequence based studies 
drawing the contours for the planned target volume (PTV) and the organs at 
risk (OARs) and generating the dose description points for image sequences 
automatically or placing groups of dose control points with the mouse for 
orthogonal image based plans. After editing the desired dose constraints for 
the various groups of dose description points the dwell times may be 
calculated automatically. 
- The results of the planning process may then be viewed in two-dimensional 
or three-dimensional representations. You may inspect each image slice as 
well as the standard views in patient space: sagittal, coronal, and transversal. 
- With the three-dimensional depiction, you may view the displayed organs, 
applicators, dose control points etc. in any orientation and view the scene 
from different angles. You may also display an isodose surface for a 
selectable dose value. Using the color coded surface dose feature, the current 
dose levels are displayed in color-coded form with pre-selected colors on the 
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structures' surfaces. 
- For evaluation of the planning results, HDRplus calculates and displays the 
various Dose Volume Histograms DVH (Cumulative DVH, Differential 
DVH and Natural DVH) as well as histogram parameters like Dxx, Vxx, 
COIN, etc. 
- After finishing the planning task, the report needs to be checked thoroughly. 
If desired, the study may be saved into an archive for later recalling. You 
may use the Patient Manager to save and retrieve studies. 
- Using the highest quality ultrasound, CT, X-Ray or MR images yields the 
best study results. Check the integrity of the imaging equipment before using 
its images for creating a new study.
(128)
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16. How to do a treatment planning with the Reco-Box 
 
1. Image acquisition: Place the Reco Box around the patient. 
- Make sure that both plates are placed in the same position. 
- Make sure that you use the correct orientation of the box and make sure that 
the side where you usually place the film is close to image intensifier. 
- In order to be able to be able to do a correct calibration of the images in the 
TPS, place a wire with a known length (e.g. 10cm) on the image intensifier. 
2. Take two images: one PA and one lateral 
- Make sure that you use the correct orientation of the box. 
- Make sure that ALL markers are visible on the images 
- Make sure the wire is visible 
- Make sure that you can see as much of the applicator as possible on the 
images. At least you have to see ALL tips of the applicators. 
- Do NOT move the box without the patient while taking the images 
3. Transfer the images to the TPS: either by DICOM transfer or by scanning the 
xray films. 
- When scanning the images a resolution of not more than 150dpi is 
recommended. 
- Make sure that you scan the images in the correct orientation. 
4. Create a new patient and a new study in HDRplus: 
- Choose the correct reconstruction method. 
5. Load both images into the HDRplus: 
- Choose the correct view/orientation for the loaded images (PA, Lat RL or Lat 
LR) 
6. Select the correct Reco Box file at Setup: 
- Choose the correct file depending on the position of the lateral markers (A, B 
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or C) and the orientation of the lateral image (LR for lateral left to right and 
RL for lateral right to left images) 
- At Setup Planning choose if the Reco Box to Film distance is variable or 
fixed. Choose Fixed if you are using x-ray films which were put in the correct 
place on the Reco box. Use Variable if you are using a digital c-arm with a 
variable distance between Reco Box and image intensifier. 
7. Calibrate the Pixel size of the images: 
- Use either the line that you have drawn on the x-ray film before scanning or 
the wire on the image intensifier to draw a line with a known length on the 
images. 
- Make sure that you select Projection from the Pulldown menue before 
drawing the line on the images. 
- Do the pixel size calibration for BOTH images. 
8. Calibrate the Reco Box: 
- Press the Reco Box Calibration button to start the calibration of the Reco Box. 
- Match the red cross with the big markers and the blue cross with the small 
markers. Calibration of the Reco Box has to be done in BOTH images. 
- Finish the calibration by clicking on the Reco Box Calibration button again. 
9. Check the calibration: 
- Place the mouse on a point which you can identify on both images, for 
example the tip the intrauterine tube. In the second image the corresponding 
orange line has to cross this point as well. 
- If it doesn‟t match, please check if you have selected the correct Reco Box 
file check if you have done the pixel size calibration and the Reco Box 
calibration correctly and if the orientation of the images (AP/PA,Lat RL/Lat 
LR) is correct.
(129)
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Figure (11) – Treatment planning with the Reco-Box(129) 
 
17. Carrying out measurements and processing of received data 
 
Data of twelve patients with cervical cancer (ten patients of squamous 
carcinoma and two of adenocarcinoma) stages T2bNxM0 (four patients) and 
T3NxM0 (eight patients) were randomly selected between the patients who have 
received combined radiotherapy at Tomsk Regional Oncology Center. 
Patients‟ age was in the range from 42 to 58 years. Patients had received 
courses of standard combined radiotherapy using EBRT with 3D-CRT (Elekta 
Synergy linac, 10 MeV, AB Elekta) or conventional radiotherapy based on 60Co 
(Theratron Equinox 100) followed by HDR BT (Multisource HDR, Bebig). The 
prescribed dose for first-stage EBRT was 50 Gy given in 25 fractions (2 Gy/fr). All 
patients received concomitant cisplatin chemotherapy weekly with the first-stage 
EBRT. 
Different irradiation techniques were compared for the second-stage of 
Radiotherapy (boost), either Brachytherapy or VMAT-boost. The first six patients 
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have received second-stage by HDR BT by dose of 30 Gy in 5 fractions (6 Gy/fr). 
The other six patients couldn't receive second-stage by HDR BT and have 
intolerance to procedure due to anatomical causes like pronounced narrowing of 
the vagina, the inability to place applicators, perforation risk, and personal or 
religious reasons to avoid the BT procedure. So they have received second-stage 
by EBRT (VMAT-boost) by dose of 30 Gy in 5 fractions (6 Gy/fr). We will 
compare tumor coverage and doses of organs at risk (OARs) included bladder and 
rectum in the two different techniques. 
 First group (HDR-BT for the second stage): 
- Six patients were scanned using the CT scanner in a supine position with 
inserted Manchester-type CT-compatible implants that were fixed well. No 
additional safety margins are needed to take into account internal movement 
during BT because the applicator moves together with the CTV.
(115)
 
- Contouring for both CTV and OARs was performed for each fraction after 
insertion of implant of BT applicators. The whole organs were contoured based 
on CT images without division on parts. As seen in Figure (12). 
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Figure (12) – Contouring for both CTV and OARs in BT. 
 
- The treatment planning goal for HDR BT was prescribed to deliver more than 
90% of the dose to 90% of the volume (D90% ≥ V90%). Dose-Volume 
Histograms (DVHs) were used for the analysis of the planning results, as seen 
in figure (13) 
- The dosimetric planning of the HDR BT of the second stage was carried out 
using the HDRplus 3D BT dose-planning system (version 3.4) for the 
MultiSource HDR apparatus with 60Co source (Bebig, Germany). 
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Figure (13) – DVHs of some patients of BT in one fraction for each 
  
 
- For OAR, it was important to specify the position of the hot spots in the 
bladder and rectum (D2cc) as this small volume may cause an impact on the 
clinical outcome. We detected dose of 2cc volume of the bladder and 2cc of the 
rectum for each patient per fraction and calculate total dose.
 (130-131)
   
- Then we calculate Biologically Equivalent Dose (BED) which is derived from 
the Linear-quadratic model and defined as: 
BED = nd [ 1 +  d / () ]
 (132) 
As n: number of equal fractions, d: dose per fraction, () is 3 Gy for the 
bladder and 3,9 Gy for the rectum.
(131)
 Then we calculated "EQD2" (equivalent 
dose in 2 Gy/fr) by equation: 
 EQD2= BED / [ 1 + 2 / () ] (132) 
Results are seen in table (3). 
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Table (3) – Physical doses, BED & EQD2 of OARs (bladder & rectum) in BT. 
HDR BT 
Urinary bladder (2cc) Rectum (2cc) 
Dose/fr total BED EQD2 Dose/fr total BED EQD2 
Patient 1 4.272 21.36 51.8 31.1 2.472 12.36 15.7 10.4 
Patient 2 1.48 7.4 11.1 6.6 2.25 11.25 17.7 11.7 
Patient 3 4.6 23 58.3 35 3.62 18.1 34.9 23.1 
Patient 4 3.55 17.75 38.8 23.3 2.82 14.1 24.3 16.1 
Patient 5 2.27 11.35 19.9 12 2.37 11.85 19.1 12.6 
Patient 6 3.8 19 43.1 25.8 1.32 6.6 8.8 5.8 
 
- DVHs of six patients received HDR BT were used to know coverage of clinical 
target volume (CTV) by different percentage of prescribed dose e.g. dose 90%, 
95%, 98%...etc. And results were collected in table (4). 
Table (4) – Coverage of (CTV) at different percentage of prescribed dose in BT. 
HDR BT 
Dose 
90% 
Dose 
95% 
Dose 
98% 
Dose 
99% 
Dose 
100% 
Dose 
109% 
Dose 
110% 
Dose 
150% 
Dose 
200% 
Dose 
250% 
Pt 1 CTV% 91.7 89.1 87.9 87.2 86.9 82.1 81.6 59.4 37.5 25.1 
Pt 2 CTV% 96.3 95.3 92.6 91.9 91.4 85.8 85.2 57.9 36.2 24.3 
Pt 3 CTV% 92.2 89.4 88.3 88 87.7 82.1 81.5 57 38.3 27.5 
Pt 4 CTV% 89.7 85.6 83.8 82.9 82 74.2 73.3 46.4 27.5 17.6 
Pt 5 CTV% 90.8 88.2 87.1 86.4 86.1 81.6 81.1 59.7 38.7 27 
Pt 6 CTV% 91.7 89.2 86.8 86.3 85.9 79.96 79.3 52.4 30.3 19.8 
 
 Second group (VMAT for the second stage): 
- Other six patients were scanned using the CT scanner in a supine position. 
Contouring for both CTV and OARs was performed based on CT images as 
seen in Figure (14). 
64 
 
 
Figure (14) – Contouring for both CTV and OARs in VMAT. 
 
- Planning was carried out using the Monaco planning system (v. 5.10.04, 
Elekta) at the Elekta Synergy linac of 10 MeV. For the VMAT technique, the 
inverse algorithms based on the Monte Carlo method were used. Plan example 
seen in figure (15) and DVH examples seen in figure (16). 
 
Figure (15) – Plan example of VMAT. 
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Figure (16) – DVH example of VMAT. 
 
- For OAR, we calculate dose of 2cc volume of the bladder and 2cc of the 
rectum for each patient per fraction and calculate total dose. Then we calculate 
BED and EQD2 from equations mentioned before. Results are seen in table (5). 
 
Table (5) – Physical doses, BED & EQD2 of OARs (bladder & rectum) in VMAT. 
VMAT 
boost 
Urinary bladder (2cc) Rectum (2cc) 
Dose/fr total BED EQD2 Dose/fr total BED EQD2 
Patient 1 5.42 27.1 76.1 45.6 5.47 27.35 65.7 43.3 
Patient 2 4.76 23.8 61.6 36.9 2.9 14.5 25.3 16.7 
Patient 3 5.16 25.8 70.2 42.1 3.89 19.45 38.9 25.7 
Patient 4 5.28 26.4 72.9 43.7 4.48 22.4 48.1 31.8 
Patient 5 5.16 25.8 70.2 42.1 4.01 20.05 40.7 26.9 
Patient 6 4.68 23.4 59.9 35.9 4.38 21.9 46.5 30.7 
 
- DVHs of six patients received VMAT boost were used to know coverage of 
target volume (CTV) by different percentage of prescribed dose e.g. dose 90%, 
95%, 98%...etc. And results were collected in table (6). 
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Table (6) – Coverage of (CTV) at different percentage of prescribed dose in VMAT. 
VMAT 
boost 
Dose 
90% 
Dose 
95% 
Dose 
98% 
Dose 
99% 
Dose 
100% 
Dose 
109% 
Dose 
110% 
Dose 
150% 
Dose 
200% 
Pt 1 CTV% 100 100 99.6 97.9 94.6 2.03 1.03 ---- ---- 
Pt 2 CTV% 100 100 98.4 95.9 91.4 3.1 1.44 ---- ---- 
Pt 3 CTV% 100 99.88 95.2 91 81 8.05 4.5 ---- ---- 
Pt 4 CTV% 100 99.6 93 86.2 79.4 0.98 0.94 ---- ---- 
Pt 5 CTV% 100 99.79 96.5 89 82.5 0.61 0.56 ---- ---- 
Pt 6 CTV% 100 99.57 95 89.2 83.3 1.08 0.87 ---- ---- 
 
 
18. Discussion of results 
 
Microsoft Excel 2010 and IBM SPSS Version 20 were used for calculations 
and for descriptive statistics. Descriptive statistics of the data are presented as 
mean ± standard deviation (SD) regarding total physical dose, BED & EQD2 
received by 2 cm3 of OARs including Bladder & Rectum in both techniques 
(VMAT & Brachherapy). Parameters are in Table (7) and figure (17). 
Table (7) – Comparison between VMAT & Brachytherapy in total physical dose, 
BED & EQD2 received by OARs (mean ± SD) 
 Brachytherapy VMAT 
Urinary 
Bladder 
Total 18.375 ± 6.05 25.8 ± 1.47 
BED 40.95 ± 18.31 70.2 ± 6.39 
EQD2 24.55 ± 11 42.1 ± 3.84 
Rectum 
Total 12.11 ± 3.76 20.98 ± 4.21 
BED 18.4 ± 8.84 43.6 ± 13.27 
EQD2 12.15 ± 5.86 28.8 ± 8.74 
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Figure (17) – Comparison between VMAT & Brachytherapy in mean of total 
physical dose, BED & EQD2 received by OARs  
 
Our study showed that the mean physical dose received by 2cm3 of Bladder 
and Rectum in Brachytherapy (18.375 ± 6.05 Gy and 12.11 ± 3.76 Gy) and in 
VMAT (25.8 ± 1.47 Gy and 20.98 ± 4.21 Gy), respectively. BEDs were calculated 
for 2cm3 of Bladder and Rectum in Brachytherapy (40.95 ± 18.31 Gy and 18.4 ± 
8.84 Gy) and in VMAT (70.2 ± 6.39 Gy and 43.6 ± 13.27Gy), respectively. Also 
EQD2 were calculated for 2cm3 of Bladder and Rectum in Brachytherapy (24.55 ± 
11 and 12.15 ± 5.86) and in VMAT (42.1 ± 3.84 and 28.8 ± 8.74), respectively. 
We found that doses received by 2cm3 of Bladder & Rectum in Brachytherapy 
lesser than doses received in VMAT.  As we know that Brachytherapy is kind of 
radiotherapy that travels a brief distance
(84)
, so the dose fall off after small distance 
from source and that make dose received by OARs lower. 
DVHs were used to detect coverage of target volume of patients at different 
variants of percentage of prescribed dose in both techniques (VMAT & 
Brachytherapy). Microsoft Excel 2010 was used for calculations of descriptive 
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statistics and plot of results in histogram. Descriptive statistics of the data are 
presented as mean ± standard deviation (SD) of CTV coverage% regarding 
variants of doses. Results are in table (8) and figure (18). 
 
Table (8) – Comparison between VMAT & Brachytherapy in coverage of CTV 
(mean ± SD) at different percentage of  prescribed  Doses. 
Dose % 
CTV coverage % by 
Brachytherapy 
CTV coverage % by 
VMAT 
90% 91.7 ± 2.25 100 ± 0 
95% 89.15 ± 3.19 99.84 ± 0.19 
98% 87.5 ± 2.86 95.85 ± 2.41 
99% 86.8 ± 2.92 90.1 ± 4.48 
100% 86.5 ± 3.04 82.9 ± 6.15 
109% 81.85 ± 3.82 1.56 ± 2.8 
110% 81.3 ± 3.94 0.985 ± 1.47 
150% 57.45 ± 5.16 ---- 
200% 36.85 ± 4.7 ---- 
250% 24.7 ± 4 ---- 
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Figure (18) – Comparison between VMAT & Brachytherapy in coverage of CTV 
(mean ± SD) at different percentages of prescribed Dose. 
 
Our study showed that the mean target coverage at 90% & 95% of the 
prescribed dose in Brachytherapy is (91.7% ± 2.25 and 89.15% ± 3.19) and in 
VMAT (100% ± 0 and 99.84% ± 0.19), respectively. Mean target coverage at 
100% & 110% of the prescribed dose in Brachytherapy is (86.5% ± 3.04 and 
81.3% ± 3.94) and in VMAT (82.9% ± 6.15 and 0.985% ± 1.47), respectively. We 
found the dose distribution over target volume is non-uniform in Brachytherapy 
and results in irradiation of significant target volumes by doses higher than 
prescribed dose, i.e., 150-200% of the prescribed dose was delivered to 57.45% 
and 36.85% of the target volume, respectively. In VMAT dose distribution over 
target volume is uniform as 98% of the prescribed dose was delivered to 95.85 of 
the target volume and hot spots don‟t exceed 110% of the prescribed dose 
delivered to about 1% only of the target volume. 
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19. Conclusion 
 
As mentioned before, there are many patients that couldn't receive second-
stage by HDR BT and have intolerance to procedure due to anatomical causes like 
pronounced narrowing of the vagina, the inability to place applicators, perforation 
risk, and personal or religious reasons to avoid the BT procedure. The results of 
our study show that the VMAT could be effective to replace HDR brachytherapy. 
Results of our study show that the use of the VMAT technique for the 
second stage of combined RT of cervical cancer allows a significant increase in the 
irradiation uniformity, to deliver the prescribed dose to the target with a high 
coverage level (99% of the target volume can be irradiated with a dose higher than 
95% of the prescribed dose), and to minimize overexposure of large volumes with 
high doses (hot spots don‟t exceed 110% of the prescribed dose delivered to about 
1% only of the target volume). 
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20. Social responsibility 
20.1 Introduction 
Cervical cancer remains the 4
th
 most diagnosed cancer and therefore the 4
th
 
leading cause of death due to cancer in women worldwide. Radiotherapy is one of 
the common types of treatment of cervical cancer and it is applied in two stages, 
first stage done by EBRT but second stage could be done by different irradiation 
techniques. Our study has compared BT & VMAT for the second stage of radiation 
in cervical cancer because some patients couldn't receive second-stage by BT and 
have intolerance to procedure due to anatomical causes like pronounced narrowing 
of the vagina, and personal or religious reasons to avoid the BT procedure. So we 
should be sure if VMAT could replace BT in this situations or not. 
20.2 Legal and organizational items in providing safety 
Nowadays one of the main way to radical improvement of all prophylactic 
work referred to reduce Total Incidents Rate and occupational morbidity is the 
widespread implementation of an integrated Occupational Safety and Health 
management system. That means combining isolated activities into a single system 
of targeted actions at all levels and stages of the production process. 
Occupational safety is a system of legislative, socio-economic, 
organizational, technological, hygienic and therapeutic and prophylactic measures 
and tools that ensure the safety, preservation of health and human performance in 
the work process.
(133)
 
According to the Labor Code of the Russian Federation, every employee 
has the right: 
- To have a workplace that meets Occupational safety requirements; 
- To have a compulsory social insurance against accidents at manufacturing 
and occupational diseases; 
- To receive reliable information from the employer, relevant government 
bodies and public organizations on conditions and Occupational safety at the 
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workplace, about the existing risk of damage to health, as well as measures to 
protect against harmful and (or) hazardous factors; 
- To refuse carrying out work in case of danger to his life and health due to 
violation of Occupational safety requirements; 
- Be provided with personal and collective protective equipment in 
compliance with Occupational safety requirements at the expense of the employer; 
- For training in safe work methods and techniques at the expense of the 
employer; 
- For personal participation or participation through their representatives in 
consideration of issues related to ensuring safe working conditions in his 
workplace, and in the investigation of the accident with him at work or 
occupational disease; 
- For extraordinary medical examination in accordance with medical 
recommendations with preservation of his place of work (position) and secondary 
earnings during the passage of the specified medical examination; 
- For warranties and compensation established in accordance with this 
Code, collective agreement, agreement, local regulatory an act, an employment 
contract, if he is engaged in work with harmful and (or) hazardous working 
conditions. 
The labor code of the Russian Federation states that normal working hours 
may not exceed 40 hours per week, The employer must keep track of the time 
worked by each employee. 
Rules for labor protection and safety measures are introduced in order to 
prevent accidents, ensure safe working conditions for workers and are mandatory 
for workers, managers, engineers and technicians. 
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20.3 Basic ergonomic requirements for the correct location and 
arrangement of researcher’s workplace  
The workplace when working with a PC should be at least 6 square meters. 
The legroom should correspond to the following parameters: the legroom height is 
at least 600 mm, the seat distance to the lower edge of the working surface is at 
least 150 mm, and the seat height is 420 mm. It is worth noting that the height of 
the table should depend on the growth of the operator. 
The following requirements are also provided for the organization of the 
workplace of the PC user: The design of the working chair should ensure the 
maintenance of a rational working posture while working on the PC and allow the 
posture to be changed in order to reduce the static tension of the neck and shoulder 
muscles and back to prevent the development of fatigue. 
The type of working chair should be selected taking into account the 
growth of the user, the nature and duration of work with the PC. The working chair 
should be lifting and swivel, adjustable in height and angle of inclination of the 
seat and back, as well as the distance of the back from the front edge of the seat, 
while the adjustment of each parameter should be independent, easy to carry out 
and have a secure fit. 
20.4 Occupational safety: 
A dangerous factor or industrial hazard is a factor whose impact under 
certain conditions leads to trauma or other sudden, severe deterioration of health of 
the worker.
(133)
 
A harmful factor or industrial health hazard is a factor, the effect of which 
on a worker under certain conditions leads to a disease or a decrease in working 
capacity. 
20.4.1 Analysis of harmful and dangerous factors that can create object 
of investigation: 
The aim of this study to carry out a dosimetric and radiobiological planning 
of the replacement of traditional combined radiation therapy [3D conformal 
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radiotherapy (3D-CRT) + high-dose-rate brachy-therapy (HDR-BT)] by 
combinations of [(3D-CRT) + (VMAT)] or [(VMAT) + (VMAT)] while 
preserving the value of the total dose delivered and the number of fractions to 
detect the best technique among russian patients at Tomsk Regional Oncology 
Center, Tomsk Polytechnic University 
20.4.2. Analysis of harmful and dangerous factors that can arise at 
workplace during investigation: 
The thesis was performed at Tomsk Regional Oncology Center. Work was 
performed using a PC. Production conditions at the workplace are characterized by 
the presence of dangerous and harmful factors, which are classified into groups: 
Elements: physical, chemical, biological, psychophysiological.The main elements 
of the production process that form dangerous and harmful factors are presented in 
Table 9. 
Table (9) – Possible hazardous and harmful factors 
Factors 
(GOST 
12.0.003-2015) 
Work stages Legal 
documents Development Manufacture Exploitation 
1. Deviation of 
microclimate 
indicators 
+ + + Sanitary rules 
2.2.2 / 
2.4.1340–03. 
Sanitary and 
epidemiological 
rules and 
regulations 
"Hygienic 
requirements 
for personal 
electronic 
computers and 
work 
2. Excessive 
noise 
  + + 
3.Increased 
level of 
electromagnetic 
radiation 
+ + + 
4.Insufficient 
illumination of 
the working 
area 
  + + 
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organization." 
Sanitary rules 
2.2.1 / 
2.1.1.1278–03. 
Hygienic 
requirements 
for natural, 
artificial and 
combined 
lighting of 
residential and 
public 
buildings. 
Sanitary rules 
2.2.4 / 
2.1.8.562–96. 
Noise at 
workplaces, in 
premises of 
residential, 
public 
buildings and 
in the 
construction 
area. 
Sanitary rules 
2.2.4.548–96. 
Hygienic 
requirements 
for the 
microclimate of 
industrial 
premises. 
5. Abnormally 
high voltage 
+ + + Sanitary rules 
GOST 
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value in the 
circuit, the 
closure which 
may occur 
through the 
human body 
12.1.038-82 
SSBT. 
Electrical 
safety. 
Maximum 
permissible 
levels of touch 
voltages and 
currents. 
6. Increased 
levels of 
ionizing 
radiation 
+ + + Sanitary Rules 
2.6.1. 2523 -0 
9. Radiation 
Safety 
Standards 
(NRB-
99/2009). 
The following factors effect on person working on a computer: 
- physical:  
o temperature and humidity;  
o noise;  
o static electricity;  
o electromagnetic field of low purity; 
o illumination; 
o presence of radiation; 
-  psychophysiological: 
o  psychophysiological dangerous and harmful factors are divided 
into:  
- physical overload (static, dynamic)  
- mental stress (mental overstrain, monotony of work, 
emotional overload). 
Deviation of microclimate indicators 
The air of the working area (microclimate) is determined by the following 
parameters: temperature, relative humidity, air speed. The optimum and 
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permissible values of the microclimate characteristics are established in accordance 
with
(134)
 and are given in Table 10. 
Table (10) – Optimal and permissible parameters of the microclimate 
Period of the year Temperature, 
C
 
Relative 
humidity,% 
Speed of air 
movement, m/s 
Cold and changing 
of seasons 
23-25 40-60 0.1 
Warm 23-25 40 0.1 
Excessive noise 
Noise and vibration worsen working conditions; have a harmful effect on 
the human body, namely, the organs of hearing and the whole body through the 
central nervous system. It result in weakened attention, deteriorated memory, 
decreased response, and increased number of errors in work. Noise can be 
generated by operating equipment, air conditioning units, daylight illuminating 
devices, as well as spread from the outside. When working on a PC, the noise level 
in the workplace should not exceed 50 dB. 
Increased level of electromagnetic radiation 
The screen and system blocks produce electromagnetic radiation. Its main 
part comes from the system unit and the video cable. According to [2], the 
intensity of the electromagnetic field at a distance of 50 cm around the screen 
along the electrical component should be no more than: 
- in the frequency range 5 Hz - 2 kHz - 25 V / m; 
- in the frequency range 2 kHz - 400 kHz - 2.5 V / m. 
The magnetic flux density should be no more than: 
- in the frequency range 5 Hz - 2 kHz - 250 nT; 
- in the frequency range 2 kHz - 400 kHz - 25 nT. 
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Abnormally high voltage value in the circuit 
Depending on the conditions in the room, the risk of electric shock to a 
person increases or decreases. Do not operate the electronic device in conditions of 
high humidity (relative air humidity exceeds 75% for a long time), high 
temperature (more than 35 ° C), the presence of conductive dust, conductive floors 
and the possibility of simultaneous contact with metal components connected to 
the ground and the metal casing of electrical equipment. The operator works with 
electrical devices: a computer (display, system unit, etc.) and peripheral devices. 
There is a risk of electric shock in the following cases: 
- with direct contact with current-carrying parts during computer repair; 
- when touched by non-live parts that are under voltage (in case of violation of 
insulation of current-carrying parts of the computer); 
- when touched with the floor, walls that are under voltage; 
- short-circuited in high-voltage units: power supply and display unit. 
  
Upper limits for values of contact current and voltage 
 Voltage, V Current, mA 
Alternate,  50 Hz 2 0.3 
Alternate,  400 Hz 3 0.4 
Direct 8 1.0 
Insufficient illumination of the working area 
Light sources can be both natural and artificial. The natural source of the 
light in the room is the sun, artificial light are lamps. With long work in low 
illumination conditions and in violation of other parameters of the illumination, 
visual perception decreases, myopia, eye disease develops, and headaches appear. 
According to the standard, the illumination on the table surface in the area of 
the working document should be 300-500 lux. Lighting should not create glare on 
the surface of the monitor. Illumination of the monitor surface should not be more 
than 300 lux. 
The brightness of the lamps of common light in the area with radiation 
angles from 50 to 90° should be no more than 200 cd/m, the protective angle of the 
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lamps should be at least 40°. The safety factor for lamps of common light should 
be assumed to be 1.4. The ripple coefficient should not exceed 5%. 
Increased levels of ionizing radiation 
Ionizing radiation is radiation that could ionize molecules and atoms. This 
effect is widely used in energetics and industry. However, there is health hazard. In 
living tissue, this radiation could damage cells that result in two types of effects. 
Deterministic effects (harmful tissue reactions) due to exposure with high doses 
and stochastic effects due to DNA destruction and mutations (for example, 
induction of cancer). 
To provide radiation safety with using sources of ionizing radiation one 
must use next principles: 
a) Keep individual radiation doses from all radiation sources not higher 
than permissible exposure; 
b) Forbid all activity with using radiation sources if profit is low than 
risk of possible hazard; 
c) Keep individual radiation doses from all radiation sources as low as 
possible. 
There are two groups of people related to work with radiation: personnel, who 
works with ionizing radiation, and population. 
  
Quantity Dose limits 
personnel population 
Effective dose 20 mSv per year in 
average during 5 years, 
but not higher than 50 
mSv per year 
1 mSv per year in 
average during 5 years, 
but not higher than 5 
mSv per year 
Equivalent 
dose per year 
in eye‟s lens 
 
150 mSv 15 mSv 
skin 500 mSv 50 mSv 
Hands and feet 500 mSv 50 mSv 
 Effective dose for personnel must not exceed 1000 mSv for 50 years of 
working activity, and for population must not exceed 70 mSv for 70 years of life. 
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In addition, for women from personnel of age below 45 years there is limit 
of 1 mSv per month of equivalent dose on lower abdomen. During gestation and 
breast feeding women must not work with radiation sources. 
For students older than 16, who uses radiation sources in study process or 
who is in rooms with increased level of ionizing radiation, dose limits are quarter 
part of dose limits of personnel. 
  
20.4.3 Justification of measures to reduce the levels of exposure to hazardous 
and harmful factors on the researcher 
Deviation of microclimate indicators 
The measures for improving the air environment in the production room 
include: the correct organization of ventilation and air conditioning, heating of 
room. Ventilation can be realized naturally and mechanically. In the room, the 
following volumes of outside air must be delivered:  
- At least 30 m 3 per hour per person for the volume of the room 
up to 20 m 
3
 per person;  
- Natural ventilation is allowed for the volume of the room more 
than 40 m 
3
 per person and if there is no emission of harmful 
substances. 
The heating system must provide sufficient, constant and uniform heating 
of the air. Water heating should be used in rooms with increased requirements for 
clean air.  
The parameters of the microclimate in the laboratory regulated by the 
central heating system, have the following values: humidity 40%, air speed 0.1 m / 
s, summer temperature 20-25 ° C, in winter 13-15 ° C. Natural ventilation is 
provided in the laboratory. Air enters and leaves through the cracks, windows, 
doors. The main disadvantage of such ventilation is that the fresh air enters the 
room without preliminary cleaning and heating. 
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Excessive noise 
In research audiences, there are various kinds of noises that are generated 
by both internal and external noise sources. The internal sources of noise are 
working equipment, personal computer, printer, ventilation system, as well as 
computer equipment of other engineers in the audience. If the maximum 
permissible conditions are exceeded, it is sufficient to use sound-absorbing 
materials in the room (sound-absorbing wall and ceiling cladding, window 
curtains). To reduce the noise penetrating outside the premises, install seals around 
the perimeter of the doors and windows. 
Increased level of electromagnetic radiation 
There are the following ways to protect against EMF: 
- Increase the distance from the source (the screen should be at least 50 cm 
from the user); 
- The use of pre-screen filters, special screens and other personal protective 
equipment. 
When working with a computer, the ionizing radiation source is a display. 
Under the influence of ionizing radiation in the body, there may be a violation of 
normal blood coagulability, an increase in the fragility of blood vessels, a decrease 
in immunity, etc. The dose of irradiation at a distance of 20 cm to the display is 50 
µrem / hr. According to the norms [2], the design of the computer should provide 
the power of the exposure dose of x-rays at any point at a distance of 0.05 m from 
the screen no more than 100 µR / h. 
Fatigue of the organs of vision can be associated with both insufficient 
illumination and excessive illumination, as well as with the wrong direction of 
light. 
Increased levels of ionizing radiation 
In case of radiation accident, responsible personnel must take all measures to 
restore control of radiation sources and reduce to minimum radiation doses, 
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number of irradiated persons, radioactive pollution of the environment, economic 
and social losses caused with radioactive pollution. 
Radiation control is a main part of radiation safety and radiation protection.  
It is aimed at not exceeding the established basic dose limits and permissible levels 
of radiation, obtaining the necessary information to optimize protection and 
making decisions about interference in the case of radiation accidents, 
contamination of the environment and buildings with radionuclides. 
The radiation control is control of: 
 Radiation characteristics of radiation sources, pollution in air, liquid 
and solid wastes. 
 Radiation factors developed with technological processes in working 
places and environment. 
 Radiation factors of contaminated environment. 
 Irradiation dose levels of personnel and population. 
The main controlled parameters are: 
 Annual effective and equivalent doses 
 intake and body content of radionuclides 
 Volume or specific activity of radionuclides in air, water, food 
products, building materials and etc. 
 Radioactive contamination of skin, clothes, footwear, working places 
and etc. 
 Dose and power of external irradiation. 
 Particles and photons flux density. 
Radiation protection office establish control levels of all controlled 
parameters in according to not exceed dose limits and keep dose levels as 
low as possible. In case of exceeding control levels radiation protection 
officers start investigation of exceed causes and take actions to eliminate this 
exceeding. 
During planning and implementation of radiation safety precautions, 
taking any actions about radiation safety and analysis of effectiveness of 
mentioned action and precautions one must value radiation safety with next 
factors: 
 Characteristics of radioactive contamination of the environment; 
 Probability of radiation accidents and scale of accidents; 
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 Degree of readiness to effective elimination of radiation accidents and 
its aftermathches;  
 Number of persons irradiated with doses higher than controlled limits 
of doses; 
 Analysis of actions for providing radiation safety, meeting 
requirements, rules, standards of radiation safety; 
 Analysis of irradiation doses obtained by groups of population from 
all ionizing radiation sources. 
Abnormally high voltage value in the circuit 
Measures to ensure the electrical safety of electrical installations: 
- Disconnection of voltage from live parts, on which or near to which work will 
be carried out, and taking measures to ensure the impossibility of applying 
voltage to the workplace; 
- Posting of posters indicating the place of work; 
- Electrical grounding of the housings of all installations through a neutral wire; 
- Coating of metal surfaces of tools with reliable insulation; 
- Inaccessibility of current-carrying parts of equipment (the conclusion in the 
case of electroporating elements, the conclusion in the body of current-
carrying parts).
(135)
 
Insufficient illumination of the working area 
Desktops should be placed in such a way that the monitors are oriented sideways to 
the light openings, so that natural light falls mainly on the left. 
Also, as a means of protection to minimize the impact of the factor, local lighting 
should be installed due to insufficient lighting, window openings should be 
equipped with adjustable devices such as blinds, curtains, external visors, etc. 
20.5 Ecological safety 
20.5.1 Analysis of the impact of the research object on the environment 
All radiotherapy centers are required to have a containment building in 
according to international requirements. The walls of containment buildings are 
several feet thick and made of concrete and therefore can stop the release of any 
radiation emitted by the reactor into the environment 
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All possible impact of radiotherapy on environment is greatly reduced in 
operating regime by many safety precautions means. The most danger of nuclear 
energy come because of different sorts of disaster  
20.5.2 Analysis of the environmental impact of the research process 
Process of investigation itself in the thesis do not have essential effect on 
environment. One of hazardous waste is fluorescent lamps. Mercury in fluorescent 
lamps is a hazardous substance and its improper disposal greatly poisons the 
environment. 
Outdated devices goes to an enterprise that has the right to process wastes. It 
is possible to isolate precious metals with a purity in the range of 99.95–99.99% 
from computer components. A closed production cycle consists of the following 
stages: primary sorting of equipment; the allocation of precious, ferrous and non-
ferrous metals and other materials; melting; refining and processing of metals. 
Thus, there is an effective disposal of computer devices. 
20.5.3 Justification of environmental protection measures 
Pollution reduction is possible due to the improvement of devices that 
produces electricity, the use of more economical and efficient technologies, the use 
of new methods for generating electricity and the introduction of modern methods 
and methods for cleaning and neutralizing industrial waste. In addition, this 
problem should be solved by efficient and economical use of electricity by 
consumers themselves. This is the use of more economical devices, as well as 
efficient regimes of these devices. This also includes compliance with production 
discipline in the framework of the proper use of electricity. 
Simple conclusion is that it is necessary to strive to reduce energy 
consumption, to develop and implement systems with low energy consumption. In 
modern computers, modes with reduced power consumption during long-term idle 
are widely used. 
20.6 Safety in emergency 
20.6.1 Analysis of probable emergencies that may occur at the 
workplace during research 
The fire is the most probable emergency in our life. Possible causes of fire: 
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- Malfunction of current-carrying parts of installations; 
- Work with open electrical equipment; 
- Short circuits in the power supply; 
- Non-compliance with fire safety regulations; 
- Presence of combustible components: documents, doors, tables, 
cable insulation, etc. 
Activities on fire prevention are divided into: organizational, technical, 
operational and regime. 
  
20.6.2 Substantiation of measures for the prevention of emergencies 
and the development of procedures in case of emergencies 
Organizational measures provide for correct operation of equipment, proper 
maintenance of buildings and territories, fire instruction for workers and 
employees, training of production personnel for fire safety rules, issuing 
instructions, posters, and the existence of an evacuation plan. 
The technical measures include compliance with fire regulations, norms for 
the design of buildings, the installation of electrical wires and equipment, heating, 
ventilation, lighting, the correct placement of equipment. 
The regime measures include the establishment of rules for the organization 
of work, and compliance with fire-fighting measures. To prevent fire from short 
circuits, overloads, etc., the following fire safety rules must be observed: 
- Elimination of the formation of a flammable environment (sealing 
equipment, control of the air, working and emergency ventilation); 
- Use in the construction and decoration of buildings of non-combustible 
or difficultly combustible materials; 
- The correct operation of the equipment (proper inclusion of equipment 
in the electrical supply network, monitoring of heating equipment); 
- Correct maintenance of buildings and territories (exclusion of the 
source of ignition - prevention of spontaneous combustion of 
substances, restriction of fire works); 
- Training of production personnel in fire safety rules; 
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- The publication of instructions, posters, the existence of an evacuation 
plan; 
- Compliance with fire regulations, norms in the design of buildings, in 
the organization of electrical wires and equipment, heating, ventilation, 
lighting; 
- The correct placement of equipment; 
- Well-time preventive inspection, repair and testing of equipment. 
In the case of an emergency, it is necessary to: 
- Inform the management (duty officer); 
- Call the Emergency Service or the Ministry of Emergency 
Situations - tel. 112; 
- Take measures to eliminate the accident in accordance with the 
instructions.
(136)
 
 
20.7 Conclusions: 
In this section about social responsibility the hazardous and harmful factors 
were revealed. All necessary safety measures and precaution to minimize 
probability of accidents and traumas during investigation are given.  
Possible negative effects on environment were given in compact form 
describing main ecological problem of using nuclear energy.  
It could be stated that with respect to all regulations and standards, 
investigation itself and object of investigation do not pose special risks to 
personnel, other equipment and environment. 
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21. Financial management, resource efficiency and resource saving. 
The purpose of this section discusses the issues of competitiveness, 
resource efficiency and resource saving, as well as financial costs regarding the 
object of study of Master's thesis. Competitiveness analysis is carried out for this 
purpose. SWOT analysis helps to identify strengths, weaknesses, opportunities and 
threats associated with the project, and give an idea of working with them in each 
case. For the development of the project requires funds that go to the salaries of 
project participants and the necessary equipment, a complete list is given in the 
relevant section. The calculation of the resource efficiency indicator helps to make 
a final assessment of the technical decision on individual criteria and in general. 
21.1. Competitiveness analysis of technical solutions: 
In order to find sources of financing for the project, it is necessary, first, to 
determine the commercial value of the work. Analysis of competitive technical 
solutions in terms of resource efficiency and resource saving allows to evaluate the 
comparative effectiveness of scientific development. This analysis is advisable to 
carry out using an evaluation card. 
First of all, it is necessary to analyze possible technical solutions and 
choose the best one based on the considered technical and economic criteria. 
Evaluation map analysis presented in Table 1. The position of your 
research and competitors is evaluated for each indicator by you on a five-point 
scale, where 1 is the weakest position and 5 is the strongest. The weights of 
indicators determined by you in the amount should be 1. Analysis of competitive 
technical solutions is determined by the formula:   
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С - the competitiveness of research or a competitor; 
Wi– criterion weight; 
Pi – point of i-th criteria. 
VMAT: Volumetric modulated arc therapy. 
BT: Brachytherapy. 
Table (11) – Evaluation card for comparison of competitive technical solutions 
 
Evaluation criteria 
 
Criterion 
Weight 
 
Points 
Competitiveness 
Taking into account weight 
coefficients 
PVMAT PBT CVMAT CBT 
      
Technical criteria for evaluating resource efficiency 
1. Risk of radiotherapy 
side effects 
0.18 4 2 0.72 0.36 
2. Dose homogeneity 0.13 5 2 0.65 0.26 
3. Dose on organs at risk 0.2 4 2 0.8 0.4 
4. Easy planning 0.14 3 5 0.42 0.7 
5.Risk of treatment failure 0.1 3 5 0.3 0.5 
Economic criteria for performance evaluation 
1. Competitive methods 0.08 5 5 0.4 0.4 
2. Power application 0.07 5 5 0.35 0.35 
3. Price 0.1 5 4 0.5 0.4 
Total 1 34 30 4.14 3.37 
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21.2. SWOT analysis: 
Complex analysis solution with the greatest competitiveness is carried out 
with the method of the SWOT analysis: Strengths, Weaknesses, Opportunities and 
Threats. The analysis has several stages. The first stage consists of describing the 
strengths and weaknesses of the project, identifying opportunities and threats to the 
project that have emerged or may appear in its external environment. The second 
stage consists of identifying the compatibility of the strengths and weaknesses of 
the project with the external environmental conditions. This compatibility or 
incompatibility should help to identify what strategic changes are needed. 
Table (12) – SWOT Analysis. 
 
Strengths: 
S1.Increase dose to tumor lead 
to increase tumor control. 
S2. Short treatment time 
Weaknesses: 
W1. 
Lack of necessary software in 
oncology clinics. 
Opportunities: 
O1. Treatment of patients 
with cervical cancer. 
O2. Reduction in patient‟s 
treatment time  
Strategy which based on 
strengths and opportunities: 
 
 
1. Acceleration of the entire 
course of Radiotherapy. 
 
Strategy which based on 
weaknesses and opportunities: 
 
 
1.  
Training of medical physicists 
to work with the inverse 
planning program  
Threats: 
T1. Lack of commercial 
interest in the project due to 
the availability of other 
VMAT techniques. 
 
 
Strategy which based on 
strengths and threats: 
1. Calculation of biological 
effective dose (BED) and 
equivalent dose in 2 Gy/fr 
(EQD2) for VMAT boost and 
Brachytherapy  boost 
 
Strategy which based on 
weaknesses and threats: 
 
1. Creation of a statistical 
database showing the 
comparison between VMAT 
boost and Brachytherapy boost. 
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21.3. Project Initiation 
The initiation process group consists of processes that are performed to 
define a new project or a new phase of an existing one. In the initiation processes, 
the initial purpose and content are determined and the initial financial resources are 
fixed. The internal and external stakeholders of the project who will interact and 
influence the overall result of the research project are determined. 
21.3.1. Stakeholders of the project 
Table (13) – Stakeholders of the project 
Project stakeholders Stakeholder expectations 
Russian oncological clinics and 
patients 
 
Availability of Radiotherapy Equipment. 
 
Medical Physicists 
 
Create radiotherapy plans. 
 
Oncologists 
 
Approve radiotherapy plans.  
 
21.3.2. Purpose and results of the Project 
Table (14) – Project purposes and expected results 
Purpose of project: To compare between VMAT boost and Brachytherapy boost in 
treatment of cervical cancer. 
Expected results of the 
project: 
1. VMAT could be effective to replace Brachythrapy 
2. VMAT allows a significant increase in the irradiation 
uniformity, 
Criteria for acceptance of the 
project result: 
1. maintenance dose to organs at risk within constraints  
 
Requirements for the project 
result: 
1. The project must be completed by June 1, 2020 of the year. 
2. The results obtained must meet the acceptance criteria for 
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the project result. 
 
21.3.3. The organizational structure of the project. 
Table (15) – The organizational structure of the project. 
№ Participant 
Role in the 
project 
Functions 
Labor 
time, 
hours. 
1 Supervisor 
Head of 
project 
Consultations. 
Review master's dissertation. 
528 hours 
 
2 Master‟s student Executor 
Writing master's dissertations. 
Compare between both techniques 
based on dose volume histogram. 
Calculate biological effective dose 
(BED) and equivalent dose in 2 
Gy/fr (EQD2) for both techniques. 
Statistical analysis of data.  
1350 hours 
 
 
21.3.4. Project limitations  
Table (16) – Project limitations. 
Factors Limitations / Assumptions 
3.1. Project's budget 310000 rub 
3.1.1. Source of financing TPU  
3.2. Project timeline: 22/07/2019 to 14/05/2020 
3.2.1. Date of approval of plan of project 20/03/2020 
3.2.2. Completion date 1/06/2020 
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21.3.5. Project Schedule 
Table (17) – Project Schedule. 
 Job title 
Duration, 
working days 
Start date 
Date of 
completion 
Participants 
General Technical 
supervision 
60 days 22/07/2019 20/09/2019 Supervisor 
Research and 
analysis of literature 
59 days 21/09/2019 19/11/2019 
Supervisor/ 
Student 
Collection of cases 
and creating 
radiotherapy plans 
 
157 days 20/11/2019 25/04/2020 
Supervisor/ 
Student 
Analysis and 
evaluation of 
results 
12 days 26/04/2020 08/05/2020 
Supervisor/ 
Student 
Preparing of 
dissertation  
26 days 09/05/2020 04/06/2020 Student 
  
A Gantt chart is a type of bar chart that illustrates a project schedule. This 
chart lists the tasks to be performed on the vertical axis, and time intervals on the 
horizontal axis. The width of the horizontal bars in the graph shows the duration of 
each activity.  
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Table (11) – Gantt chart of Project Schedule 
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4 
Analysis and 
evaluation of 
results 
Supervisor
/ 
Student 
12          
 
  
5 
Preparing of 
dissertation  
Student 26             
 
21.4. Scientific and technical research budget. 
The amount of costs associated with the implementation of this work is the 
basis for the formation of the project budget. This budget will be presented as the 
lower limit of project costs when forming a contract with the customer. 
To form the final cost value, all calculated costs for individual items related 
to the manager and the student are summed. 
In the process of budgeting, the following grouping of costs by items is 
used: 
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- Material costs of scientific and technical research; 
- Costs of special equipment for scientific work (Depreciation of 
equipment used for design); 
- Basic salary; 
- Additional salary; 
- Labor tax; 
- Overhead. 
Name 
Material 
costs 
Costs of 
special 
equipment 
Basic 
salary 
Additional 
salary 
labor tax Overhead Total cost 
Cost, 
rubles 8,030 19,000 143,224 10,922 48,521 57,643 287,340 
The budget for scientific and technical research is shown in table: 
  
21.4.1. Calculation of material costs. 
The calculation of material costs is carried out according to the formula: 
  (2) 
where  m – the number of types of material resources consumed in the 
performance of scientific research; 
Nconsi – the amount of material resources of the i-th species planned to be 
used when performing scientific research (units, kg, m, m
2
, etc.); 
Pi – the acquisition price of a unit of the i-th type of material resources 
consumed (rub./units, rub./kg, rub./m, rub./m
2
, etc.); 
kТ – coefficient taking into account transportation costs. 
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Prices for material resources can be set according to data posted on relevant 
websites on the Internet by manufacturers (or supplier organizations). 
Energy costs are calculated by the formula: 
  (3) 
where  − power rates (5.8 rubles per 1 kWh); 
 − power of equipment, kW; 
 − equipment usage time, hours. 
Table (19) – Material Costs. 
Name Unit Amount 
Price per unit, 
rub. 
Material costs, 
 rub. 
Electricity of computer kWh 150 5.8 870 
Papers  300 1 300 
Printing on A4 sheet  400 4 1,600 
Pen  3 150 450 
Transportation and 
procuring expenses 
 100 21 2,100 
Internet Month 5 1000 5,000 
Total 10,320 
21.4.2. Cost of special equipment. 
Equipment was not specifically purchased for this work, therefore, it is necessary 
to calculate costs associated with this special equipment (devices and mechanisms 
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fixation, special Software necessary to carry out work  for example in this work Monaco 
Treatment Planning System (TPS)) all of those  cost about 15,000.  
21.5. Basic salary. 
This point includes the basic salary of participants directly involved in the 
implementation of work on this research. The value of salary costs is determined 
based on the labor intensity of the work performed and the current salary system. 
The basic salary (Sb) is calculated according to the following formula: 
  (4) 
where   Sb – basic salary per participant; 
Тw – the duration of the work performed by the scientific and technical 
worker, working days; 
Sa - the average daily salary of  participant, rub. 
The average daily salary is calculated by the formula: 
  (5) 
where  – monthly salary of an participant, rub .; 
М – the number of months of work without leave during the year: 
at holiday in 48 days, M = 11.2 months, 6 day per week; 
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– valid annual fund of working time of scientific and technical personnel 
(251 days). 
Table (20) – The valid annual fund of working time 
Working time indicators  
Calendar number of days 365 
The number of non-working days 
- weekend 
- holidays 
 
52 
14 
Loss of working time 
- vacation 
- sick absence 
48 
The valid annual fund of working time 251 
Monthly salary is calculated by formula: 
  (6) 
where  Sbase – base salary, rubles; 
kpremium – premium rate;  
kbonus – bonus rate; 
kreg – regional rate. 
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21.5.1. Supervisor base salary. 
The basic salary of the supervisor is calculated on the basis of the sectoral 
labor payment. The sectoral wage system in TPU assumes the following 
composition of wages. The salary is determined by the enterprise.  
In TPU, salaries are distributed in accordance with the positions held. The 
head of this research work is an employee with the position of an associate 
professor The salary of the senior teacher is 35120 rubles. 
The wage increments are 10000 rubles (surcharges of the academic 
council), and the district coefficient for Tomsk Region is 1.3. 
Basic Salary of Supervisor: 35,120 *1.3 = 45,656 rub 
(45,500 * 10.4)/251 = 1,891.7 rub/day 
In total of days: 1,891.7 rub/day * 288 days = 544,809.6 rub 
21.5.2. Master student salary. 
Since master student basic salary is 17,310 
Basic Salary of master student: 17,310*1.3 = 22,503 rub 
(22,503 *10.4)/251 = 932.4 rub/day 
In total of days: 932.4 rub/day * 254 days = 236,829.6 rub  
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Table (21) – Calculation of basic salary. 
Participant Basic salary, rubles 
Head of project 544,809.6 
Student 236,829.6 
Total 781,639.2 
 
21.5.3. Additional salary. 
This point includes the amount of payments stipulated by the legislation on 
labor, for example, payment of regular and additional holidays; payment of time 
associated with state and public duties; payment for work experience, etc. 
Additional salaries are calculated on the basis of 10-15% of the base salary 
of workers: 
  (7) 
where  Wadd – additional salary, rubles; 
kextra – additional salary coefficient (10%);  
Wbase – base salary, rubles. 
Table (22) – Calculation of Additional Salary. 
 Supervisor  Master student  
Basic salary, rub/month 544,809.6 236,829.6 
Additional salary, rub  54,481 23,683 
Total 78,164 
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21.5.4. Labor tax. 
Tax to extra-budgetary funds are compulsory according to the norms 
established by the legislation of the Russian Federation to the state social insurance 
(SIF), pension fund (PF) and medical insurance (FCMIF) from the costs of 
workers. 
Payment to extra-budgetary funds is determined of the formula:  
  (8) 
where  kb – coefficient of deductions for labor tax. 
In accordance with the Federal law of July 24, 2009 No. 212-FL, the 
amount of insurance contributions is set at 30%. Institutions conducting 
educational and scientific activities have rate - 27.1%. 
Table (23) – Calculation of Labor tax. 
 Supervisor  Master student  
Coefficient of deductions 27.1% 
Salary, rubles 544,809.6 236,829.6 
Labor tax, rubles 147,643.4 64,180.8 
Total  211,824.2 
  
21.5.5. Overhead costs. 
Overhead costs include other management and maintenance costs that can 
be allocated directly to the project. In addition, this includes expenses for the 
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maintenance, operation and repair of equipment, production tools and equipment, 
buildings, structures, etc. 
Overhead costs account from 30% to 90% of the amount of base and 
additional salary of employees. 
Overhead is calculated according to the formula: 
  (9) 
where kov – overhead rate. 
Table (24) – Calculation of Overhead 
 Supervisor  Master student  
Overhead rate 30% 
Salary, rubles 544,809.6 236,829.6 
Overhead, rubles 326,885.8 71,048.9 
Total  397,934.7 
  
21.5.6. Formation of budget costs. 
The calculated cost of research is the basis for budgeting project costs. 
Determining the budget for the scientific research is given in the table. 
Table (25) – Budget for scientific and technical research. 
Name Cost, rubles 
1. Material costs 10,320 
2. Costs of special equipment 15,000 
3. Basic salary 781,639.2 
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4. Additional salary 78,164 
5. Labor tax 211,824.2 
6. Overhead 397,934.7 
Total planned cost 1,494,882.1 
  
21.6. Conclusion 
Thus, in this section was developed stages for design and create 
competitive development that meet the requirements in the field of resource 
efficiency and resource saving. 
These stages includes: 
- Development of a common economic project idea, formation of a 
project concept; 
- Organization of work on a research project; 
- Identification of possible research alternatives; 
- Research planning; 
- Assessing the commercial potential and prospects of scientific 
research from the standpoint of resource efficiency and resource saving; 
- Determination of resource (resource saving), financial, budget, social 
and economic efficiency of the project. 
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